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ELASTOGENIC CHARACTERIZATION OF RAT BM-MSC-DERIVED SMCS 
TOWARDS USE IN SOFT TISSUE ENGINEERING 
SAHITHYA WINTRICH 
ABSTRACT 
The inherently poor capacity of post-neonatal vascular smooth muscle cells 
(SMCs) to synthesize elastin and biomimetically assemble elastic matrix structures is a 
major limitation to our present ability to tissue engineer functional vascular replacements. 
Therefore, we presently seek to ascertain if SMCs freshly differentiated from bone 
marrow mesenchymal stem cells (BM-MSCs), are elastogenically superior or comparable 
to mature, adult aortic SMCs, which would justify their use as elastogenic cell sources for 
vascular tissue engineering. We also seek to determine as to how BM-MSCs 
differentiation protocols influence the quality and quantity of elastic matrix deposition. 
Rat BM-MSCs treated with PDGF-BB (50 ng/mL) and TGF-β1 (5 ng/mL), were 
differentiated on human fibronectin (hFN) coated wells for 7 and 14 days respectively 
and number-expanded in the presence of factors for 7 days in uncoated flasks. 
Immunohistochemistry data for SMC specific markers showed positive staining for α-
SMA in PDGF-BB and TGF-β1 (7 and 14 day) treated BM-MSCs compared to controls 
where as all the cultures expect expressed Calponin BM-MSCs treated without cytokines 
for 7 days. Quantitative analysis revealed that α-SMA is more intensely expressed per 
cell in PDGF-BB treated BM-MSCs for 7 days when compared to the other conditions, 
whereas, TGF-β1 treated BM-MSCs for 14 days had the highest intensity of antibody per 
cell for Calponin. Flow cytometry results indicated that BM-MSCs differentiated with 
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TGF-β1, especially for 14 days more intensely express SMC markers, especially a-SMA 
compared to other markers. Cell cycle analysis indicated that hFN-coated substrate does 
not affect differentiation capacity or BM-MSCs and treated with TGF-β1 exhibit a greater 
number of cells in the G1 phase of the cell cycle compared to PDF-BB-treated BM-
MSCs. Real time polymerase chain reaction (RT-PCR) data show higher expression of α-
SMA, SMMHC and LOX in BM-MSCs differentiated for 7 and 14 days with and without 
cytokines compared to BM-MSCs and the greatest expression in BM-MSCs 
differentiated in the absence of cytokines for 14 days. Elastin gene expression was 
greatest in the 14 day TGF- β1 treated cultures and there was no difference in gene 
expression between treatment or control groups for Caldesmon. Cell proliferation data 
showed that 7 day differentiation groups had lower cellular proliferation and BM-MSCs 
treated with PDGF-BB and TGF-β1 for 14 days had lower expression compared to 
others. Comparing the effect of differentiation time, those cultured for 14 days showed 
lower cellular proliferation in all groups except SMCs. Like wise, fold change data 
exhibited that TGF-β1 treated BM-MSCs for both 7 and 14 days were far less 
proliferative than any other group. BM-MSCs treated with PDGF-BB produced greater 
amounts of insoluble and soluble elastin compared to all other groups. No significant 
differences between BM-MSCs treated and untreated with cytokines for 7 and 14 day and 
control cell lines were found in the amounts of collagen and LOX activity except SMCs. 
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CHAPTER I  
INTRODUCTION 
 
1.1 Cardiovascular disease 
According to the American Heart Association (AHA), over 82.6 million 
American adults (1 in 3) are afflicted with one or more types of cardiovascular disease 
(CVD). A 40% increase in the prevalence of CVD is estimated by the year 20301. Over 
the last 100 years, more deaths occurred due to CVD than any other major source of 
mortality in the United States of America (Figure 1.1). In addition to the population 
attrition rate, the estimated direct and indirect cost of CVD for 2008 was $297.7 billion 
and is projected to triple by 2030 to $818 billion1. Major risk factors that contribute to 
CVD are high blood pressure, elevated levels of serum cholesterol, high body mass 
index, diabetes mellitus, smoking and obesity. The risk of developing CVD increases 
with family history of CVD with the highest increase in risk with the existence of 
premature CVD in the family member1. 
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Figure 1.1. Major causes of death for all males and females in the United States (2008). A = CVD plus 
congenital heart disease, B = cancer, C = accidents, D = chronic lower respiratory disease, E = diabetes 
mellitus, F = Alzheimer disease. Source: NCHS/NHLB 1 
 
Atherosclerosis, a major contributor of CVD, is a systemic disease that is 
associated with significant morbidity and mortality. It affects multiple vascular beds, in 
various large and small arteries as well as those feeding the heart (coronary artery), brain 
(carotid artery), kidneys (renal artery), and extremities (peripheral arteries). A classic 
characteristic of this disease is the hardening of arterial walls due to the build up of 
plaque. Plaque results from the accumulation of fat, cholesterol, extracellular matrix 
(ECM) components and other substances such as calcium. This phenomenon can cause 
inflammation, scar tissue formation, cell recruitment and cell adhesion. Over time, this 
leads to narrowing of blood vessels, causing flow restriction or acute surface thrombus 
formation from platelet deposition. The major consequences of atherosclerosis are heart 
attack, stroke and aneurysms. The life-threatening effects of this disease have different 
outcomes based on the size of the blood vessels. In larger diameter arteries, disease is 
brought on because of ischemia to tissues that surround occluded vessels from thrombus 
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formation, embolism, or plaque rupture. Atherosclerosis afflicting smaller diameter 
vessels, typically less than 3 mm in diameter, can lead to significant morbidity due to loss 
of function in the peripheral limbs or their loss due to gangrene leading to severe post 
surgical complications 1–3. 
Atherosclerosis can initiate secondary to vascular injury from physical, chemical 
or microbial attacks, diseases such as diabetes, poor nutrition or inadequate physical 
activity. While some diseases and poor lifestyle choices can be controlled by the 
cessation of smoking, diet control and increase in physical activity, the pathogenesis of 
atherosclerosis in response to vascular injury result in more life threatening 
manifestations of the disease and require more aggressive treatments1. 
1.2 Current treatment options and limitations 
 Several therapeutic and preventative treatment options are available today to help 
manage the risk factors associated with atherosclerosis and decrease the incidence of 
surgical intervention thereby reducing costs. However, clinical treatment options for 
severe debilitating manifestations of the disease including minimally invasive and 
surgically invasive procedures have now become available, providing a thrust in the 
development of new devices and technologies or improve existing ones. 
Therapeutic and preventative treatment options for treating atherosclerosis may be 
designated as either primary or secondary. Primary options include cholesterol- and lipid- 
lowering statin therapies, anti-hypertensive therapies such as thiazide diuretics (ACE 
inhibitors, α-blockers, calcium channel blockers), aspirin, antiplatelet and anti-thrombotic 
agents4. Secondary treatment options often include lifestyle modification strategies such 
as weight reduction via exercise and diet control as well as smoking cessation. Current 
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trends of therapeutic and preventative treatments often include a combinatory approach in 
which several pharmacologic agents (polypill treatments) are administered along with 
recommended lifestyle changes. While these have indeed shown to lower the risk factors 
associated with of CVD in several clinical trials, high mortality rates and increased 
morbidity due to severe CVD events still exist and require additional invasive solutions4. 
Minimally invasive procedures to treat cardiologic disorders involve the use of a 
stent – stainless steel prosthesis inserted via balloon angioplasty, designed to prop open 
the occluded vessel to maintain it patent. While the initial placement of the stent is 
minimally-invasive via laparoscopic procedures, the process of catheter insertion often 
damages the lumen of blood vessels exposing the underlying cell layers to blood 
components with the potential of thrombus formation. Therefore based on the vessel 
morphology and clinical situation, its success is temporary with restenosis – a repeat 
narrowing of the blood vessel, known to occur in about 30-60% of cases within 6 months 
of implantation even though stenting improves cardiac function5. The treatment of 
restenosis often requires an additional surgical procedure contributing to significant 
morbidity mortality and high costs5. 
For small diameter vessels that cannot be treated via angioplasty or larger vessels 
that have been severely compromised by disease, bypassing them using vascular graft 
conduits may be necessary to maintain blood supply to peripheral tissues/organs. The 
gold standard for such grafts has been the use of an autologous tissue source, typically the 
saphenous vein or mammary artery. Tissues for such grafts are obtained surgically and 
therefore result in morbidity in the area and great patient discomfort. Moreover, the 
autologous vascular tissue available for replacement may not be suitable or of sufficient 
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length for replacement due to systemic vascular disease in the patient6–8. To overcome 
this limitation, allogeneic or xenogeneic (e,g, porcine) vascular tissues may be used for 
grafting. Such tissues must however be decellularized and processed to remove donor 
epitopes – a part of an antigen recognized by antibodies, and chemically cross-linked to 
stabilize as well as preserve matrix structures against enzymatic disruption. The 
processing techniques employed can conversely alter tissue mechanics and compliance. 
Although decellularization and chemical treatment prevents inflammation and infection, 
failure due to size mismatch and graft versus host disease seems inevitable. These 
drawbacks have promoted the development and use of synthetic grafts such as Dacron 
and polytetrafluoroethylene (PTFE) that sufficiently mimic the mechanical properties of 
native blood vessels and elicit a reduced thrombogenic response6.  
Synthetic grafts remain less optimal solutions and have several limitations for 
replacement in small-diameter vessels. One major drawback is that synthetic grafts are 
generally stiffer and far less compliant than naturally available grafts such as autografts, 
allografts and xenografts9. This mismatch is a major contributor to adverse long-term 
effects such as restenosis and intimal hyperplasia in the region of anastomosis10. Another 
critical shortcoming of synthetic grafts is that they have poor capability to endothelialize 
in humans beyond the region of anastomosis. The lack of endothelial cells to inhibit 
smooth muscle hyper-proliferation, and platelet adhesion, encourages these grafts to 
develop a platelet and collagen rich fibrous layer ultimately causing thrombosis5,6. In 
large diameter blood vessels (> 6 mm wide) however, thrombosis does not pose as a 
major issue since the surface area to volume ratio is low compared to smaller vessels and 
blood flow is considerably faster.  Consequently, a given thrombus volume occludes a 
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much smaller luminal area fraction of the graft relative to a smaller graft. In small 
diameter vessels (<6 mm wide), blood flows at a slower rate and is in contact with the 
graft for a longer period since surface area to volume ratio is high. A decreased blood 
velocity increases the time of interaction between platelets and vascular graft causing 
their deposition and contributing to thrombosis5,6. Therefore, a completely tissue 
engineered small vascular graft (TEVG) would be highly necessary and desirable.  
1.3 Tissue engineered vascular grafts (TEVG) and their limitations 
Occlusive plaques afflicting small-caliber vessels are not easily treated 
angioplasty, with and without stenting, or bypass synthetic graft procedures, because a) 
long, diffuse lesions, and tortuous channels that render the procedures difficult and b) 
propensity to thrombose and re-stenose thereby limiting long-term success of the 
procedures or performance of the grafts. Tissue engineering has emerged as a promising 
approach to address the deficiencies of current options.  
Tissue engineering (Figure 1.2), as stated by Langer and Vacanti11 is “an 
interdisciplinary field that applies the principles of life sciences and engineering toward 
the development of biological substitutes that restore, maintain, or improve tissue 
function or a whole organ”11. It utilizes 1) living cells as engineering materials, 2) 
scaffolds (biological or synthetic, but biodegradable) to mimic in vivo tissue structures, 
enhance cell adhesion, growth or differentiation as well as provide mechanical stimuli to 
resident cells, 3) biochemical factors to enhance biological function and 4) bioreactors, 
devices that simulate physiological environments by providing controlled culture 
conditions including temperature, oxygen and carbon dioxide concentrations, pH and 
mechano-transductive stimulation to cells11,12.  
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Figure 1.2 A schematic showing the different components of tissue engineering. Source: Wikimedia 
Commons; Image available online from http://commons.wikimedia.org/wiki/Main_Page 
 
In vascular tissue engineering, general principles of tissue engineering are applied 
to develop tubular constructs known as tissue engineered vascular grafts (TEVG)7. To 
produce a TEVG several aspects of the native blood vessels need to be replicated 
particularly, its structure and mechanical properties. The cells that become the source of 
ECM and biomimetic cues become critical design criteria to fulfill the necessary 
requirements of sustained vascular function and tissue structure6,7. 
Adult endothelial cells (ECs), smooth muscle cells (SMCs) and fibroblasts have 
been used in the last two decades by several groups, to develop TEVG, by culturing the 
cells on various types of scaffolds. Collagen, fibrin, decellularized porcine vascular 
matrices, and other biodegradable polymer scaffolds including polyglycolyic acid (PGA), 
poly(lactic-co-glycolic acid) (PLGA), Polycaprolactone (PCL), poly-L-lactide (PLLA), 
and poly-4-hydroxybutyrate (P4HB)6,7,13 have been used as scaffold materials but with 
limited success. The inadequate mechanical compliance of the tissue constructs that are 
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generated has been a major deterrent to their successful long-term survival. This is due to 
challenges in replicating native vessel ECM composition and architecture within TEVGs, 
primarily with respect to ECM components such as elastin / elastic fibers that adult cell 
types are poorly capable of synthesizing and assembling. Hence in this context, using 
terminally differentiated autologous adult cell types can be problematic with the structure 
of ECM produced by these cells seldom matching that of during development6,7,13. While 
progress has been made with adult cells as sources for TEVG, circumferential alignment 
of SMCS, collagen fibers and elastic lamellae is still being investigated. Although some 
groups have reported mature elastin fibers by fibroblasts, elastic matrix produced by adult 
SMCS is still an open question. Additional limitations of such cells are a) invasive 
procedures to obtain healthy vessels for cell isolation, b) difficulties in procurement of 
healthy vascular tissues from patients, especially those with synthetic vascular disease, 
and c) need for prolonged period of expansion in vitro prior to use for vascular tissue 
engineering applications6,7,13. Due to these drawbacks, alternative autologous cell sources 
such as stem cells have been considered towards use in generation TEVG.  
1.4 Bone marrow mesenchymal stem cells (BM-MSCs) for vascular grafts 
The inherently poor ability of adult somatic cells to produce sufficient elastin 
precursors and assemble them into matrix structures that mimic that in native vascular 
tissues has promoted the study of stem cells as autologous cell sources for TEVG. 
 Stem or progenitor cells are characterized by their capacity for self-renewal and 
differentiation into other specialized cell types under the influence of specific signals and 
microenvironments with a phenotype that is distinct from the predecessor14,15.  While this 
fundamental characteristic yields them the potential for use in cell-based clinical 
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cardiovascular treatments and organ regeneration, two other qualities confer ‘stemness’ 
to these cells. The first is, the expression of specific molecular markers termed stem cell 
markers and the second is the ability to execute specialized cell effects14. 
The bone marrow is a major source of stem cells in the adult body. The 
mononuclear cell fraction of the marrow, a rich source of progenitor cells, can be 
obtained by Ficoll-Paque density centrifugation. These progenitor cells are known as 
bone marrow mononuclear cells (BM-MNCs) and are heterogeneous populations 
containing endothelial precursor cells (EPCs), mesenchymal stem cells (MSCs), HSCs, 
and monocytes among others16.  
MSCs can be harvested from almost every organ in the body but, due to variations 
in differentiation capabilities to specific cell phenotypes and limitations to yield, MSCs 
harvested and separated from the bone marrow (typically iliac crest) (BM-MSCs) are the 
most commonly used sources of stem cells for developing TEVG14,16,17. They can be 
separated from other BM-MNC populations by plating the entire fraction and culturing 
only the adherent population or through cell sorting for those with specific surface 
markers. They are capable of self-renewal, rapid expansion and differentiation into a 
variety of phenotypes such as bone, fat, cartilage, muscle, tendon and cardiovascular cell 
types14,16,17. One additional characteristic in their favor is that they are non-immunogenic 
in nature when allografted because they lack the major histocompatibility complex II and 
have been shown by recent studies to play a role in angiogenesis by the secretion of 
various factors to recruit additional stem cells for reparative purposes. Despite the 
favorable features, BM-MSCs occupy a tiny fraction of the BM-MNCs (about 0.01%) 
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and this percentage and differentiation capability has been shown to decrease with 
increasing age 14,16,17. 
Several studies have investigated the use of BM-MSCs in vascular tissue 
engineering and assessed the patency of TEVG18. In one study, BM-MSCs labeled with 
green fluorescent protein (GFP) were seeded onto polyurethane (PU) scaffolds and 
surgically implanted into the aorta of a Sprague-Dawley rat. After two weeks, it was 
observed that BM-MSCs had proliferated and organized into multiple tissue layers that 
mimicked the layers of the aortic wall tissue. Immunohistochemistry showed cells to 
express SMC-specific phenotypic markers such as alpha smooth muscle actin (αSMA), 
smooth muscle myosin heavy chain (SMMHC), indicating their differentiation, at least in 
part, SMCs19. In other work, in vivo transplantation of BM-MSC-seeded electrospun 
PLLA conduits into rat carotid arteries showed it to exhibit long-term survival of the graft 
due to the non-immunogenic nature of BM-MSCs. Histology showed the MSC-seeded 
scaffold to contain newly deposited ECM including collagen and some elastin20.  
Despite the above findings, significant unknowns exist in the field, most notably, 
the lack of any data pertaining to the ability of BM-MSCs or their derivatives to 
synthesize and assemble ECM structures, more specifically, elastin/elastic matrix that are 
biological, structural and functional replicates of native vascular ECM, is a serious 
limitation to their proposed use for vascular tissue engineering applications. Elucidating 
these unknowns is that a critical need towards enabling generation of biomimetic and 
functional vascular tissue replacements, and is the focus of the present study. 
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1.5 Problem statement and thesis objective 
An autologous cell source for TEVG is a potential solution for overcoming 
maladies due to CVD such as atherosclerosis. For conditions where the microcirculation 
is affected and small-diameter arteries undergo significant damage, TEVG remain the 
only hope of treatment. However, since adult vascular cells fundamentally have poor 
regeneration capabilities, the use of stem cells for this application seems logical. The low 
immunogenic potential of MSCs render them appropriate cell types for tissue 
regenerative therapies. Differentiation of MSCs into SMCs has been successfully 
demonstrated with past studies. However, the ability of these cells to synthesize elastin 
precursors and assemble them into elastic matrix structures that resemble native vascular 
ECM, which is crucial to the proper functioning of blood vessels, has not been studied. In 
investigating this aspect, we hypothesize that differentiated stem cells would exhibit a 
higher elastic matrix regenerative capacity more closely resembling neonatal or fetal cell 
populations than adult vascular cells.  
The objective of this study is to substantiate prior claims of bone marrow 
mesenchymal stem cells (BM-MSCs) as a potential cell source for growing TEVGs. The 
specific aims of this study are as follows: 
1. Investigate impact of choice of differentiation growth factor and differentiation 
time on phenotype of vascular smooth muscle cells derived from rat BM-MSCs.  
2. Assess the level of differentiation by biochemical studies testing for SMC specific 
proteins.  
3. Evaluate the gene expression of SMC specific genes.  
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4. Estimate the elastogenic capability of BM-MSCs by measuring the quality and 
quantity of elastin synthesized by the differentiated cells.  
1.6 Organization of thesis 
Chapter 2 provides an overview of the structure and function of the vasculature, 
the etiology of occlusive and dilatory vascular disease, treatment options that exist on the 
market today, a discussion of TEVG and their limitations, stem cell as elastogenic cell 
sources and the characterization of stem cell derived smooth muscle cells.  
Chapter 3 provides in detail the experimental methods used for in vitro 
differentiation of BM-MSCs and the procedures used to evaluate the successful 
differentiation and cell culture. Chapter 4 illustrates results obtained from the 
experiments listed in Chapter 3. Chapter 5 provides interpretations of the results from 
Chapter 4 and the conclusions to be drawn from this study, and also Chapter 6 
summarizes current findings and lists recommendations for future work to further 
substantiate the same.  
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CHAPTER II 
BACKGROUND 
 
2.1 Vascular physiology 
The cardiovascular system in animals is unique in its capacity to handle high 
blood volumes while maintaining relatively constant systemic pressure throughout the 
cardiac cycle due to the presence of large elastic arteries. The capacity of these vessels to 
store potential energy due to stretching of the vessel wall during cardiac systole 
(emptying of blood by the heart) is crucial to the proper cardiac function.  This stored 
energy propagates the flow of blood volume downstream to the arterioles during the rest 
or filling phase of the cardiac cycle resulting in an even flow throughout the arterial 
tree21. To appreciate the mechanism by which vascular homeostasis is maintained in 
healthy functioning arteries, it is necessary to understand the underlying components of 
the arterial vessels including the cells, ECM constituents and their organization.  
The arteries comprise of three major concentric layers or ‘tunics’ delimited by 
two sheet-like layers of ECM proteins (membrane limitans interna and membrane 
limitans externa). Each tunic contains specialized cells and an ECM of characteristic 
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composition and structure22.  In order of appearance from the lumen of the artery these 
three layers are tunica intima, tunica media, tunica adventitia (Figure 2.1).  
 
Figure 2.1 The three layers of the artery. (A) Schematic drawing22 (B) H & E stained image of the cross-
section of a muscular artery. Source: Color images available at: 
http://www.lab.anhb.uwa.edu.au/mb140/corepages/vascular/vascular.htm 
 
Tunica intima  
The tunica intima consists of a thin layer of a) squamous endothelial cells 
anchored to a basement membrane, b) a thin sheet of subendothelial connective tissue 
below the basement membrane and c) an inner limiting membrane that separates the tunic 
intima from tunica media. The basement membrane serves as a foundation to anchor 
endothelial cells and is comprised of collagen IV, XV and XVIII, laminins and 
proteoglycans such as perlecan – a heparin sulfate proteoglycan. The basement 
membrane, with the assistance of laminins participates in inflammation by regulating 
diapedesis i.e. the migration of white blood cells from the blood stream into adjoining 
injured tissue, via the vessel wall. Proteoglycans bind to growth factors and influence 
cellular function, such as proliferation of endothelial cells (ECs), and contribute to the 
anti-thrombogenicity of the vessel under normal conditions. The ECs secrete various 
A. B.
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cytokines and growth factors to assist their function: non-thrombogenic and non-
leukocyte-adherence factors, vasoconstrictive and vasodilative molecules such as nitric 
oxide and other regulatory agents. The major function of the tunica intima lining the 
luminal surface of the arteries is to serve as a permeability barrier between blood and 
surrounding tissue21–23.  
 
Tunica media  
The tunica media is the thickest of the three vascular tunics comprised mostly of 
contractile SMCs that generate ECM, including elastin (which forms up to 50% of the 
vessel’s dry weight), and collagen types I and III. The vascular SMCs are found 
sandwiched between concentric, circumferentially aligned elastic lamellae and 
proteoglycan rich ECM. The elastic lamellae, with their ability to stretch and store energy 
provide the blood vessel resilience to pulsatile hemodynamic forces during the cardiac 
cycle. Collagen, in the media has several important functions- 1) provides tensile strength 
to the blood vessel, 2) bears the additional load of mechanical stretching with the elastic 
lamellae and 3) prevents vessel overexpansion and resultant rupturing21–23.  
 
Tunica adventitia  
The tunica adventitia is the outermost layer of the artery that is mostly made of 
fibroblasts connecting the blood vessel to the nearby connective tissue. The adventitia is 
surrounded by the vasa vasora, small capillaries that provide nutrients to this layer that is 
removed from the blood conducting lumen. The matrix of the adventitia is characterized 
by high collagen content and glycosaminoglycans produced by resident fibroblasts. The 
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adventitia is the primary load-bearing layer of a blood vessel. The collagen prevents 
rupture of the vessel at extremely high pressures21,22. 
2.2 Vascular extracellular matrix and mechanics 
The vascular ECM is an extensive network present in all three tunics and confers 
a blood vessel the unique property of stretch and recoil to accommodate hemodynamic 
stresses during pulsatile blood flow. A process of enzymatic degradation and limited new 
matrix (matrix turnover) by the resident vascular cells continually maintains the integrity 
of the vascular matrix in a blood vessel. Importantly, the structure and components of this 
matrix regulate the function, behavior and phenotypes of vascular cells by functioning as 
biochemical signaling molecules24. Building a functional matrix requires a concerted 
expression of certain genes encoding for ECM proteins secreted out of the cells as well as 
enzymes that assemble them to form a network21,22. Of all the extracellular components, 
collagen, glycosaminoglycans (GAGs) and elastin are the major players in vascular 
structure and function. 
 
Collagen 
The most abundant protein in the vascular ECM is collagen which is primarily 
responsible for providing tensile strength and structure to blood vessels. Several cell 
types produce collagen in the vascular ECM. For example, in the intima and media 
vascular SMCs produce this protein whereas in the collagen in the adventitia is produced 
entirely by fibroblasts. The collagen protein can polymerize to form ultra structures such 
as non-elastic fibers, sheets and fibrils with the distribution varying depending on the 
vascular region21,24.  
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The collagen family of proteins contains triple helical rod-like domains 
constructed by three α chains characterized by a high content of proline, hydroxyproline 
and glycine in every third position of the amino acid sequence. In the adult vasculature, 
collagen types I, III, IV, V, VI, VIII, XV, XVIII and XIX are found and generally 
grouped together based on their structural role – fibrillar, sheet forming, fibril associated 
or microfibrillar (Figure 2.2) 21,24.  
 
Figure 2.2 A schematic of collagen monomers and polymers illustrating the assembly of the 
macromolecule24.  
 
Fibrillar collagens (types I, III and V) are the most abundantly found protein in 
vascular tissue forming networks of fine fibrils and large fiber bundles distributed 
throughout the tissue. Monomers of this protein are secreted as procollagen and modified 
extracellularly and aligned longitudinally in a staggered arrangement to form fibers. 
These fibers are the major structural elements of vascular tissue running longitudinally in 
the intima and adventitia and spirally in the muscular media21,24. Sheet forming collagens 
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(types IV and VIII) are predominantly found in the basement membrane underlying EC 
and basal lamina surrounding SMCs. The monomers of this type of collagen can 
associate to form tetramers, which can further interact with other monomers to form a 
planar network. Fibril-associated collagens (types XV, XVIII, XIX) also contribute to the 
structure of the basement membrane of small and large vessels although; the details of 
their function are unknown. Microfibrillar collagens are fine networks underlying the 
sheet-forming collagens of endothelial basement membrane.  The monomers join to form 
tetramers that join end-to-end generating beaded filaments. These are known to serve as 
anchor points for other types of collagens21,24.  
 In addition to providing mechanical support to the vessel wall, collagen in the 
adventitia prevents the blood vessel from over extending in response to stretching during 
systole. Also, it has been shown that collagen regulates cell attachment and 
differentiation. Furthermore, SMCs in a collagenous microenvironment are known to 
assume a more contractile and less ECM-generating phenotype21,24. 
 
Glycosaminoglycans 
Glycosaminoglycans (GAGs) are polysaccharide chains covalently bonded to 
proteoglycans (amino acids associated with sugar molecules). GAGs constitute the 
ground substance of the vascular ECM. The bulk of the GAGs are synthesized by 
vascular SMCs in response to signaling growth factors such as PDGF and TGF-β21,24 but, 
ECs are also known to produce GAGs which are incorporated into the basement 
membrane. Hyaluronan, condroitin sulfate, dermatan sulfate and heparin sulfate are 
commonly found GAGs in vascular tissue. These polysaccharides are long unbranched 
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molecules of repeating disaccharide units with sulfated or carboxylated groups. These 
groups render GAGs a high density of negative charge. Thus, GAGs exhibit high affinity 
for water, making proteoglycans gel-like structures with the ability to withstand 
compressive forces when bound to collagen. GAGs contained in the endothelial basement 
membrane give the membrane an overall negative charge, thereby assisting in its 
filtration capabilities. Proteoglycans associated with ECs in the luminal surface also 
deliver anticoagulant properties to this layer21,24.  
 
Elastin  
The major ECM protein that imparts the property of elasticity to blood vessels is 
elastin and is mostly present in the medial layer of vascular tissue. The elastic fiber 
network of the media is produced by vascular SMCs and organized into concentric sheet 
like structures called lamellae within the medial layer of the vessel (Figure 2.3). The 
elastin of the lamellae is arranged in fenestrated sheets with collagen fibers, thin layers of 
proteoglycan rich ECM and SMCs sandwiched in between. Elastic fibers then connect 
the lamellae together into a three dimensional continuous network and to the SMCs21–
23,25.  
The majority of elastic fibers are synthesized and assembled during early 
development and adult tissues have limited capability of regenerating this complex 
network. Elastic fibers are composed of two distinct components, namely, a core of 
amorphous, cross-linked elastin protein, surrounded by electron-dense 10-15 nm long 
glycoprotein microfibrils, fibrillin. The fibrillin is first laid down as a pre-scaffold prior 
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to coacervation and crosslinking of elastin precursors (tropoelastin). Elastic fibers are 
typically 100nm - 1µm in diameter21,26,27. 
 
Figure 2.3 A schematic of a blood vessels showing the distribution of elastin between a muscular artery 
(left) and elastic artery (right)25. 
 
Tropoelastin, is a 60-70 kDa protein with hydrophobic sequences alternating with 
lysine containing domains. After being secreted into the ECM, tropoelastin precursors 
associate with microfibrils forming amorphous cross-linked elastin. Lysyl oxidase 
(LOX), an enzyme present in the ECM, further covalently crosslinks lysine residues on 
the elastin molecules to other tropoelastin molecules, in the process rendering elastic 
matrix structures highly insoluble and resistant to enzymatic degradation (Figure 2.4A). 
The elastin molecule has multiple domains – α-helical regions where cross-links are 
formed and β sheets with hydrophobic components. The elastic fibers are further linked 
to form fiber meshes and continuous or fenestrated sheets21,26,27. These protein domains 
can be stretched reversibly, extending up to 220% of their original length (Figure 
2.4B)21,22.	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Figure 2.4 (A) A schematic of elastin synthesis and assembly into elastic fibers27. (B) An elastic fiber 
during stretch and recoil with covalently cross-linked domains shown in red28.  	  
Due to its distensibility, the elastic matrix acts as an elastic reservoir. It has low 
tensile strength and distributes stress from mechanical stretching onto collagen lining the 
vessel wall (Figure 2.5). These remarkable properties of elastin bestow the vessel its 
resilience to the pulsatile pressures. During systole of the cardiac cycle, SMCs in the 
media relax, increasing the distance between elastic lamellae and the diameter of the 
vessel. Elastic lamellae and fibers store this mechanical energy. In diastole, the opposite 
occurs where SMCs contract, reducing the distance between elastic lamellae and 
decreasing the diameter of the vessel. The energy stored in the elastic lamellae due to 
stretching, is transferred as kinetic energy to blood, propelling it downstream. In addition 
to its structural role, elastin regulates vascular SMCs by inhibiting their proliferation and 
maintaining them in a quiescent state. The collagen fibers between the elastic lamellae, 
provide the vessel with tensile strength and limit vessel expansibility (Figure 2.5)21,22. 
A. B. 
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Figure 2.5 Stress-strain curve for a blood vessel29. The stress-strain curve shows the low tensile strength of 
elastin accommodating large blood volumes by stretching and high tensile strength of collagen resisting 
overexpansion of blood vessel walls with little stretching while bearing the load of high blood volumes. 
 
2.3 Etiology of occlusive and dilatory vascular disease 
Atherosclerosis is the most common form of arteriosclerosis, a term that describes 
any cardiovascular pathology that involves the occlusion of arteries and calcific stiffening 
of their walls, thereby reducing their elasticity. It is a primary source of cerebral and 
myocardial infarction, gangrene of the extremities, loss of function of organs and/or 
tissues and is a major contributor to the mortality rate in the United States and worldwide. 
Over the years, this most widely accepted mechanism for the pathogenesis of 
atherosclerosis is the 'response-to-injury' theory (Figure 2.6). Based on this theory, 
atherosclerosis is a specialized form of a protective, inflammatory response to various 
forms of injury to the arterial wall. Current viewpoints on this theory add that injury to 
the endothelium and other vascular cells begin at specific sites in the arterial tree and 
characterized by chronic inflammatory response23.  
  23 
 
Figure 2.6 The response of injury model of atherosclerosis. Clockwise from top right: 1) Exposure to 
oxidizing agents and and increased monocyte and macrophages adherence 2) cell migration to 
subendothelium and lipid accumulation 3) formation of fibrotic lesion 4) development of plaque and 
thrombus 5) potential reversal of occlusion with treatment. oxLDL = oxidized LDL 23. 
 
Atherogenesis  
Injury to the endothelial lining of the tunic intima initiates the recruitment of 
peripheral blood monocytes and T-lymphocytes, which adhere to the luminal 
endothelium. Activation of these leukocytes occurs with monocytes converting to 
macrophages and T-lymphocytes replicating within the vessel wall. The activated cells 
express a series of genes for cytokines and growth factors such as platelet derived growth 
factor BB (PDGF-BB), epidermal growth factor, fibroblast growth factor and 
transforming growth factor β1 (TGF-β1). These cytokines released into the ECM, 
promote the phenotypic change of the quiescent SMCs causing them to proliferate and 
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migrate to the region of inflammation where they produce abundant ECM. The final 
outcome of this process is the development of plaque in the intima that slowly encroaches 
the vessel lumen, forming an atherosclerotic lesion comprised of three major cell 
components – synthetic SMCs and lymphocytes in the fibrous cap and macrophages in 
the necrotic core and various amounts of lipids and associated lipoproteins. The advanced 
form of these lesions are fibrous plaques that can take two forms – an asymmetric 
thickening of the intima or symmetric due to an immune rejection such as the placement 
of transplanted tissues or devices. Atherosclerotic lesions have shown to progress 
becoming occlusive, eventually leading to thrombosis or may be dislodged and travel to 
distant vessel as an embolism17,22,23,30,31 . 
Injury to the lumenal endothelial lining may have several sources leading to its 
dysfunction. Hyperlipidemia, the presence of excessive fats in blood, is the most common 
cause of injury. Cholesterol, low-density lipoproteins (LDL) and very low-density 
lipoproteins (VLDL) circulating the in blood tend to accumulate at specific sites in the 
arterial tree and become oxidized upon uptake by the endothelium. The oxidized lipids 
act as chemoattractants and enhance monocyte (macrophages, T-lymphocytes and 
leukocytes) recruitment and adhesion to intimal endothelial cells near fatty deposits. 
Along with increasing the permeability of vascular tissue to plasma lipoproteins, blood 
borne growth factors and oxidized lipids, the resident immune cells recruit more 
monocytes to the same region thus triggering an immune response cascade with 
infiltrating platelets and contributing to the developing plaque. Other contributors to 
atherosclerosis include hypertension, diabetes, poor lifestyle such as smoking and 
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consumption of dietary fats or even infectious agents such as viruses or other 
pathogens17,22,23,30,31.  
 
The role of SMCs in vascular health and disease  
In the developing embryo, vascular SMCs originate from multiple locations. 
Coronary artery SMCs are derived from epicardial lining of the mesoderm, SMCs of the 
aortic arch are derived from the neuroectoderm and SMCs of the descending aorta are 
derived from the local mesenchyme17,32. Regardless of their origin, considerable 
differences can be noted in their gene expression patterns32,33. In late embryogenesis and 
post-natal development, SMCs are know to be highly prolific, synthesizing ECM 
components such as collagen, elastin, proteoglycans, cadherins, and integrins at high 
rates contributing to the initial blood vessel structure17,32. In mature adult vessels 
however, the resident terminally differentiated SMCs contain the necessary receptors, ion 
channels, signal transduction molecules, calcium regulatory proteins, and proteins 
necessary for healthy contractile activity important to maintaining vascular tone and 
exhibit low proliferation and ECM synthesis17,22.  
Vascular SMCs can interchange between the contractile and synthetic phenotypes, 
although a continuum exists between the two, under certain physiologic or pathologic 
conditions. When the intact vessel is injured these quiescent SMCs are exposed to plasma 
constituents and lipids, activating them to a more synthetic phenotype by altering their 
gene expression and protein synthesis. Synthetic SMCs migrate from the media to intima, 
proliferate profusely and produce abundant amounts of ECM. Their de-differentiation 
into a synthetic phenotype is further exacerbated under the influence of cytokines and 
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growth factors such as PDGF-BB, TGF-β1 and fibronectin, which are typical for 
regenerating tissue. Under their reparative role, SMCs increase their production of matrix 
degrading proteins – matrix metaloproteases (MMP) and compromise vessel structure 
leading to rupture, thrombosis and embolism formation17,22.  
2.4 Treatment options 
Preventative and pharmacological treatments  
Lifestyle changes often encompass preventative measures to decrease the onset of 
atherosclerosis. The consumption of polyunsaturated fats (omega-6 and omega-3) has 
demonstrated reduction in the progression of atherosclerosis by reducing inflammatory 
molecules31. Foods with a high glycemic index such as refined carbohydrates from grains 
and sugars have been associated with the generation of inflammatory markers and 
reactive oxidation species leading to diabetes, a high risk factor for CVD31. Diets with 
highly refined carbohydrate consumption have been associated with reduced levels of 
essential cofactors and antioxidants such as ascorbate, carotene, thiamine, folate, 
riboflavin and vitamins A and E31. This deficiency has been shown to contribute to 
further injury to the vascular wall under inflammatory driven oxidative stress. Ascorbic 
acid has been shown to prevent endothelial dysfunction, inhibit switching of SMCs from 
a quiescent to synthetic phenotype, and reduce oxidized LDL uptake and degradation by 
macrophages31. Similarly, vitamin E has been held responsible for reducing other 
inflammatory markers31. Therefore a diet rich in fruits, vegetables, whole grains, 
unrefined sugars and polyunsaturated fats may mitigate the progression of 
atherosclerosis. In addition to diet changes, cessation of smoking and increasing daily 
physical activity may further help prevent or stabilize atherosclerosis31.  
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Pharmacological treatments for atherosclerosis include the use of statins. Statins 
target 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase to lower plasma 
lipids like cholesterol and inhibit inflammatory cytokines such as IL-1β	   by	   affecting	  endothelial	   gene	   expression31,34.  Additional benefits of using statins are (1) they 
improve the production of nitric oxide, an endothelial derived relaxing factor and nitric 
oxide synthase, promoting vasodilation (2) inhibit the expression of the vasoconstrictor 
endothelin-1 (3) suppress adhesion molecules and cytokine and/or chemokine production 
(4) reduce thromogenicity in endothelial cells34.  
 
Endovascular treatments 
Endovascular treatments for occluded vessels include percutaneous transluminal 
angioplasty (PCTA) and stents. In PCTA, a catheter bearing either a deflated balloon or 
laser tip is inserted into the occluded artery. In the case of balloon angioplasty, the 
balloon is inflated near the lesion to expand the artery and compact the occluding plaque. 
With laser angioplasties, the energy from the laser is used to ablate the plaque. 
Alternatively, ablative angioplasty where a co-axially mounted rotating knife removes 
plaque build up by the use of opposite low-pressure balloon is used to treat 
atherosclerosis5,35.  
The use of a self-expanding or balloon expandable stent, i.e., a metal or polymer 
mesh covered with polyester fabric, polyurethane or silicone membrane is another 
approach to treating atherosclerosis. Stents are often deployed using a catheter in which 
the device is stored in a compressed state to be expanded upon delivery to the 
atherosclerotic site. Shape memory alloys such as nitinol have been used in the last two 
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decades allowing customization of the device to arterial size. In order to prevent an 
immune response, drug-eluting stents tethered with antiplatelet and/or anticoagulatory 
drugs inhibit neointima formation. More recently biodegradable stents have been 
developed to overcome limitations of their metallic and polymer counterparts5,35. 
 
Vascular grafts  
In situations where the artery is so diseased that catheters are impassable to treat 
stenosis, surgical intervention becomes the only treatment option. Vascular grafts used to 
bypass the stenosed arterial segment can be autologous – healthy vessels of comparable 
diameter e.g. saphenous veins or synthetic.  
Vascular autografts are segments of healthy arterial tissue excised from the 
patients themselves and grafted to bypass the diseased or occluded vessel segment. The 
gold standard for vascular autografts is the saphenous vein or mammary artery for blood 
vessels of the heart or lower extremities. Autografts have several advantages. The bypass 
procedure is cost-effective when compared to alternatives. The use of autologous tissue 
promotes revascularization and is non-immunogenic in nature. This procedure preserves 
the patient quality of life better than limb amputation. However, their availability may be 
limited or may not be suitable for certain applications6,8.  
For patients whose saphenous vein or mammary artery is unavailable for grafting 
from being harvested previously or due to systemic disease, use of synthetic grafts 
present an alternative approach. Polymers commonly used for synthetic vascular 
prostheses are crystalline, hydrophobic materials that are often reinforced with supporting 
rings or coils for long prostheses. Common graft materials include polyethylene 
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terephthalate (PET) also called Terylene or Dacron6 and polytetrafluoroethylene 
(PTFE)6,8, ordinarily known as Teflon or Gore-Tex (expanded PTFE - ePTFE) its 
molecular variant. Other frequently used polymers are polyurethane (PU) and its 
variants6.  
PET or Dacron is a thermoplastic polymer resin used to make fibers bundled into 
yarns that can be woven or knitted into grafting tubes. Tubes made of knitted Dacron can 
be infused with proteins such as albumin, collagen or gelatin for decreasing porosity and 
easy graft integration, but these effects are temporary with protein degradation occurring 
within a short time of grafting. Grafts made of ePTFE are non-textile tubes made by 
heating, stretching and extruding. It is more stable in biological systems, less susceptible 
to degradation and immune response than PET, but more susceptible to thrombotic 
occlusion, especially in smaller diameter vessels6. Polycarbonate-based polyurethane is 
stable from degradation due to hydrolysis or oxidation. It promotes endothelization, 
reduces amounts of neointimal formation and is better compliant than PET or ePTFE6.  
2.5 Limitations of present treatment options 
Preventative and pharmacological treatments 
Managing risk factors such as diet related obesity, smoking, reduced physical 
activity, consumption of refined carbohydrates and sugars undoubtedly help in the 
treatment of atherosclerosis but cannot be followed in isolation. While consumption of 
foods rich in antioxidants suppresses the oxidation of circulating lipids, this approach is 
more of a preventative rather than treatment for severely diseased vessels. The immune 
reaction that accompanies atherosclerosis warrants other aggressive treatments31.  
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While statins have shown to reduce progression of atherosclerotic plaque by 
lowering serum lipid levels, promoting endothelial function by increasing the expression 
of vasodilators together with the suppression of vasoconstrictors30,34, they modestly 
reduce restenosis3 therefore the need for additional therapies. 
 
Endovascular treatments 
Balloon angioplasty temporarily expands diseased vessels and restores blood 
flow. However, within six months of the procedure, the vessel lumen is reduced by 50% 
and re-stenosis occurs in about half the cases. Implantation of stents/stent grafts reduces 
the incidence of re-stenosis but in about 40% of the cases, the condition still persists. The 
high cost of this procedure and dangers of restenosis makes this minimally invasive 
treatment a less optimal treatment option especially for small diameter vessels5,35. 
 
Vascular grafts 
Roughly, 30-40% of the patients needing a bypass procedure lack appropriate 
vascular tissue due to prior phlebitis, vessel harvest, varicosities hypo-plasia, or 
anatomical mismatch. Even if the autologous tissue was available, severe donor site 
morbidity due to surgical removal seems inevitable6. Saphenous vein grafts are liable to 
atherosclerosis and intimal hyperplasia for the patency period. To circumvent these 
problems, synthetic grafts are frequently used in the present day6. 
Even though synthetic grafts are the second best option to autologous sources of 
vascular grafts, results are not optimal in terms of healing and tissue regeneration. 
Immune response to the synthetic graft is inevitable and begins almost immediately with 
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serum protein adhesion, platelet deposition, monocyte recruitment and eventually SMCs 
migration, proliferation and ECM production leading to thrombosis and occlusion of the 
prosthesis. Despite half a century of development, prosthetic grafts have varied patency 
rates. Long-term patency rates in blood vessels larger than 8 millimeters (90% patency 
for aorto-iliac substitutes)6,8 are no different for medium-sized vessels between 6-8 mm. 
For smaller vessels that less than 6 mm, their outcomes are disappointing with patency as 
low as 39% for above the knee bypass grafts when compared to 74% patency rate for 
autologous venous bypass6,8.  
Synthetic grafts fail due to thrombogenicity and intimal hyperplasia at the distal 
anastomosis (the site where the graft is connected to native tissue) developing within the 
first year. Compliance mismatch between the rigid prosthesis and compliant artery tissue, 
graft and artery diameter mismatch, lack of cellularization of the graft by vascular cells, 
surgical trauma and over-proliferation and ECM production by synthetic SMCs 
contribute to unsatisfactory results with their use6. Over the years, they have been 
improved with coatings of anti-coagulant, anti-thrombogenic and anti-immunogenic 
agents. However, neither has prevention of infection nor patency rates improved to a 
100%. In order to produce a biocompatible graft, introducing biological components such 
as cells to synthetic grafts seem like the most logical choice6. 
The requirements of an ideal vascular graft are many. The graft material must be 
strong and compliant to withstand long term hemodynamic stresses, non-toxic, non-
immunogenic and non-thrombogenic, biocompatible, easy to handle and suture during 
surgical procedures, integrate seamlessly into the host, able to grow with host tissue when 
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placed in children, available off the shelf in various sizes, economical, and have a high 
shelf life6. 
One method of improving biocompatibility is encouraging the formation of an 
endothelial layer inside the graft's lumen. In vivo, post implantation this can occur three 
ways - by ingrowth from the native artery from the anastomosed site, vascular tissue 
ingrowth through the graft or circulating endothelial progenitor cells. In vitro, endothelial 
cells have been seeded onto the synthetic grafts and cultured for 2-4 weeks prior to 
implantation. The cell seeded synthetic constructs have been exposed to hemodynamic 
forces such as circumferential cyclic stretching, shear stress from fluid flow in the 
laboratory to induce structural changes and adaptation prior to implantation. Patency rates 
for these grafts have been about 60% and are believed to close the gap between 
autologous and synthetic grafts. To improve clinical success, several ECM molecules 
such as collagen, laminin and fibronectin have been investigated to support better 
adherence of the endothelial layer to the graft6. The incorporation of native matrix 
structures that contribute to vessel mechanics such as collagen and elastin are critical for 
graft survival and function. Circulating progenitor cells and genetically modified cells 
have been considered as alternative cell sources for use with synthetic grafts. While these 
constructs improve host integration and patency rates, they still have a limited lifespan 
and don't adapt to the changes in native tissue at the anastomized regions6.  
2.6 Tissue engineered vascular grafts and their limitations 
A living totally-engineered blood vessel (TEBV) or tissue engineered vascular 
graft (TEVG) can overcome deficiencies of synthetic grafts with or without biological 
components, via their ability to remodel, grow, self-repair and respond to biological 
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signals in the vascular tissue microenvironment. Ideally, such as graft would be 
composed of cells and ECM arranged in three-dimensional (3-D) layers just as in a native 
blood vessel. The lumen of the graft would be lined by an endothelium to prevent 
thrombosis, quiescent contractile SMCs circumferentially aligned with elastin or its 
analogue for sufficient recoil under hemodynamic forces, and with fibroblasts in the outer 
most layer with collagen to provide high tensile strength and support6,7. One underlying 
assumption in the design criteria is that the intricate design of native arteries may not be 
identically replicated with tissue-engineered constructs7. Several studies have attempted 
to produce TEVG with EC, VSMC and fibroblasts seeded within tubes of compacted 
collagen gels with Dacron mesh reinforcements for mechanical strength6,7. Four 
approaches have broadly tackled the design goals described: 1) decellularized tissues, 2) 
synthetic polymer scaffolds, 3) cell sheets via tissue assembly and 4) hydrogels or 
biopolymer scaffolds.  
 
Decellularized tissues 
Decellularized tissues from autologous sources are composed of natural ECM 
with native mechanical properties and biocompatibility. Other scaffold materials used are 
decellularized and cross-linked porcine aorta and small intestinal submucosa6. They can 
be vascular or non-vascular tissues that have been treated with detergents, enzyme 
inhibitors and buffers to remove resident cells and immunogenic epitopes. Although 
decellularized vascular tissues grossly retain the structure and composition of native 
vessels, treatment conditions cause significant shrinkage possibly due to the stripping of 
proteoglycans. Allogeneic decellularized grafts undergo aneurysms, infection and 
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thrombosis7. In order to circumvent these issues, decellularized tissues cross-linked with 
glutaraldehyde reduces enzymatic degradation but in the process, compromise vascular 
mechanics causing stiffening of these tissues. Also, remnants of donor epitopes can 
stimulate adverse immune responses and cell debris. Accumulation of cellular debris can 
act as focal points for matrix mineralization in the patient leading to tissue stiffening and 
rupture6,7. 
 
Synthetic scaffolds 
The use of biodegradable scaffolds seeded with vascular cells has been 
investigated. One advantage to using biodegradable polymers is the ability to control 
scaffolding parameters such as microstructure, mechanical properties, rate of resorption, 
and to coordinate the degradation of the scaffold with regeneration of new tissue by 
seeded cells, which would seem to take over the mechanics of the construct. Though 
polyglycolic acid (PGA) is the most used polymer for tissue engineering applications its 
rapid resorption leads to premature weakening of the construct. PGA has been 
copolymerized with polylactic acid (PLA), polyhydroxyalkanoate (PHA), poly-4-
hydroxybutyrate (P4HB), polycaprolactone-co-polylactic acid (PCL/PLLA) and 
polyethylene glycol (PEG) to overcome this limitation. Since cells are seeded after the 
fabrication of these scaffolds to prevent them from apoptosis due to relatively toxic 
construction conditions, cell distribution may be severely uneven leading to poor results. 
In addition to that failure of the polymer scaffold prior to adequate ECM generation by 
the cells can be catastrophic7.  
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Cell sheets 
In this approach, different vascular cells are cultured in vitro with factors that 
induce ECM production for a period of time and the cell/matrix generated is detached 
from the substrates as a sheet and wrapped in layers around a porous tubular mandrel and 
conditioned with perfused culture medium. Typically cell/matrix sheets containing SMCs 
and fibroblasts respectively are concentrically wrapped around the other and allowed to 
fuse together to form a tube with two distinct layers resembling the tunica media and 
tunica adventitia respectively. ECs are seeded later along the tube lumen within a 
mechanically rotated bioreactor7. Gauvin et. al.36 used a self-assembly approach of tissue 
engineering wherein SMCs and fibroblasts were experimented with, in three different 
ways. Rolling a single cell sheet of SMCs or fibroblasts separately, rolling the 
fibroblastic adventitia on top of the SMCs medial layer and rolling of a single cell sheet 
comprising both SMCs and fibroblasts were used to produce the medial and adventitial 
layers of vascular tissue. Using this approach, they demonstrated that the single-step 
assembly process enhanced ultimate tensile strength, linear modulus and linear modulus 
ration when compared to other assembly methods. The single step approach has the 
advantage of handling the tissue once reducing the risk of contamination and tear. The 
mechanical properties of their constructs were improved by the ECM produced by SMCs 
and fibroblasts36. A significant disadvantage in their study is that they did not culture 
these in a 3-D environment nor did they investigate the elastic capabilities of these 
vessels in response to hemodynamic stresses. The ability of the cells to generate matrix 
structures was also not particularly investigated. 
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Biopolymer scaffolds 
Biopolymer based scaffolds can be designed to provide through contact guidance, 
alignment to seeded cells, and through this process, modulate their levels and patterns of 
ECM synthesis. Typically, monomers of ECM proteins such as fibrin and collagen are 
mixed with vascular cells such as SMCs and allowed to polymerize and compact to 
generate cellularized constructs7. When compaction is constrained, fibers of the ECM 
protein are generated along the axis of constraint, which provide via contact guidance, 
alignment to cells. In this manner, circumferential alignment of cells to mimic that in the 
tunica media can be achieved. The poor mechanical strength of these constructs, despite 
enzymatic cross-linking of the extracellular monomers by cells is however a problem7. 
Addition of growth factors such as TGF-β1 has been shown enhance elastogenesis of 
SMCs and improve cross-linking of these matrix proteins within such 3-D constructs to 
improve tissue mechanics7,37.  
Other approaches to generate biomaterials that mimic vascular ECM fibrillar 
structure, viscoelasticity, cell adhesion domains, growth factor binding, and proteolytic 
sensitivity have emerged. Electrospinning, a technique in which a polymer solution is 
drawn as a fiber onto a rotating mandrel in the presence of a large potential difference, 
has been used to produce scaffolds containing defined fiber alignments/orientations. 
Although this technique can generate scaffolds containing circumferentially-aligned 
fibers, the inability to incorporate cells during the fabrication process and their limited 
ability to infiltrate through the closely placed scaffolding fibers, if seeded post-fabrication 
is a severe constraint to ensuring cell viability and matrix regeneration within these 
scaffolds7. 
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Meeting the vascular tissue engineering design requirements seems to be a tall 
order today. Constructs engineered by current approaches don't encompass all design 
criteria. No approach has demonstrated all the key features necessary in a successful 
substitute for the tunica media - circumferential alignment of adult SMCs, collagen fibers 
and elastic lamellae. The pursuit of stem cells to produce mature elastic fibers 
comparable to that found in native vascular ECM remains a goal of tissue engineering. 
Most of the elastin produced so far by tissue engineering is in the amorphous form and 
producing elastic fibers circumferentially aligned in a vascular graft remains a challenge. 
Therefore tissue engineering with adult stem cells seem promising. For example, Roh et. 
al.38 demonstrated that vascular grafts seeded with BM-MNC develop into TEVG driven 
by the process of inflammation rather than a stem cell mediated process by the secretion 
of monocyte chemoattractant protein - MCP-1. Their findings suggest that stem cells 
seeded on vascular grafts act as a source of multiple cytokines that induce angiogenesis, 
arteriogenesis and cytoprotection rather than differentiate into vascular cells 
themselves38. 
2.7 Stem cells as elastogenic cell sources 
The ability of the cardiovascular system to accommodate the range of 
hemodynamic forces encountered due to pressure and blood volume changes during the 
cardiac cycle is due to the complex structure, composition and alignment of ECM and 
associated cells within vascular tissue. Elastin, a major component of this matrix confers 
blood vessels their elasticity, serves as a framework for adherence of resident SMCs, and 
regulates their phenotype via biomechanical transduction, while providing tissue 
elasticity, to maintain cardiovascular homeostasis. Unfortunately, terminally 
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differentiated adult SMCs are inherently poor in synthesizing elastin precursors and 
assembling and cross-linking them into mature elastic fibers and further into functional 3-
D matrix structures. This becomes a serious limitation to our ability to grow elastic 
matrix-rich vascular replacements that resemble native tissues. 
Small diameter vascular grafts suitable to replace blood vessels less than 6 
millimeters are the target of current tissue regeneration research39. The limited 
availability and expandability of adult vascular cells, specifically SMCs and their poor 
capacity to biomimetically regenerate elastic matrix structures either in vivo at sites of 
proteolytic disease, or in vitro culture, have led to the investigation of stem cells 
alternate, more elastogenic cells sources for tissue engineering. The ability of stem cells 
to self-renew and to differentiate into daughter cells of with specialized function such as 
SMCs renders them useful to investigate as alternate SMC sources18,40. 
Stem cells are of several types, e.g. embryonic stem cells (ESCs) or embryonic 
germ stem cells, induced pluripotent stem cells (iPSCs), and tissue-resident or adult stem 
cells14,17. ESCs are obtained from embryos resembling a hollow sphere comprising 200 to 
250 cells known as blastocytes. Embryonic germ stem cells come from 5 to 9 week old 
fetuses that can develop into ovaries or testes. ESCs have a unique ability to differentiate 
into all cell types of an adult organism and therefore are known as totipotent stem cells. 
iPSCs are a result of reprogramming adult differentiated cells (e.g. fibroblasts) into a 
state of pluripotency, which indicates that they can be differentiated into most if not all 
possible cell lineages. Adult stem cells, can originate from the umbilical cord, placenta, 
blood, bone marrow, skin and other tissues14,17. Those that reside in the in bone marrow, 
peripheral blood and umbilical cord are termed hematopoietic stem cells (HSC). Those 
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residing predominantly in the bone marrow stroma where they are maintained a quiescent 
stem cell pool, are termed bone marrow mononuclear cells (BM-MNCs). Each stem cell 
type has its advantages and limitations. ESCs can cause tumorogenesis and raise ethical 
issues with their procurement form fertilized human embryos, even though this allogeneic 
source is able to differentiate into any cell type desired. iPSCs are a better source due to 
their autologous origin that enables patient customized therapies with their ‘embryonic-
like stemness’ and the lack of ethical issues pertaining to their sourcing, although a lack 
of robust characterization to date limits their use. Therefore, autologous or allogeneic 
adult stem cells seem the logical choice for use in tissue engineered cell therapies14,17.  
BM-MSCs are a favorable source for tissue engineering and regenerative 
therapies because of their relative ease of isolation, high expansion ratio, low 
immunogenicity, antifibrotic and antiapoptotic propertries, and release pro-angiogenic 
factors18,40. They have the ability to differentiate into various cell types including SMCs 
or ‘SMCs-like’ in vitro and in vivo18,39–41.  Several approaches have been attempted 
including differentiation media, growth factors such as PDGF-BB and TGF-β40 and 
material used for the vascular construct. Additionally, since their microenvironment 
greatly affects their differentiation and matrix production, parameters such as soluble 
signaling factors, substrate topography and rigidity and mechanical stimulation can be 
used to control the differentiation outcomes and the quality and quantity of matrix 
production18.  
The ultimate characteristic of a full functioning TEVG is an elastic biological 
prosthesis that provides the mechanical properties of the native blood vessels it is sought 
to replace. In an attempt to produce just that, several groups investigated the potential for 
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differentiation of BM-MSCs into vascular SMCs. However, very little information is 
available regarding the matrix synthesis capabilities of the derived cells, and that relative 
to adult SMCs, particularly with regard to elastic matrix. 
The major factors contributing to successful vascular differentiation of BM-MSCs 
isolated from BM-MNCs are the culture conditions, scaffold or substrate properties, 
exogenous cytokine addition, mechanical forces resident in the environment (in vitro or 
in vivo) and genetic modification. Several scaffolds have been used to construct TEVG 
seeded with MSC such as decellularized allogenic grafts, polyurethane, 
polylacticglycolic-acid16 and polyesterurethane42. Substrates coated with extracellular 
components such as collagen-coated acrylamide gels43, tissue culture dishes coated with 
laminin (LM), collagen type IV (Col-IV), fibronectin44 have been used to differentiate 
BM-MSC to vascular smooth muscle cells (SMCs). Variations in the culture medium 
formulations composing of different serum concentrations, cytokines, vitamins and 
minerals abound to coax BM-MSC towards vascular SMCs differentiation33,43.  The 
stiffness of the matrix upon which BM-MSC are cultured can influence and determine the 
differentiation and commitment toward a specific cell lineage. The matrix strength is also 
a factor that contributes to the amounts of ECM produced by the differentiated cells43. 
Shear stress by incorporating flow of culture medium within these grafts when cultured in 
vitro, is used to mimic the hemodynamic forces that native vessels experience16. In 
addition to the nutrient rich media, several cytokines have been added to BM-MSC for 
differentiation toward SMCs – bone morphogenetic protein 242, all trans-retinoic acid45, 
transforming growth factor beta-133,46, ascorbic acid46, platelet derived growth factor-
BB33, transforming growth factor beta-341. Genetic modifications of BM-MSC to express 
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endothelial nitric oxide synthase (eNOS) at native vessel levels have also been tried to 
confer further antithrombogenic properties16. 
Tamama et. al.39 showed that blocking the ERK/MAPK pathway up-regulates 
SMCs gene expression in BM-MSC. The ERK/MAPK is an extracellular signal regulated 
protein kinase or mitogen activated protein kinase pathway that is anti-myogenic. 
Inhibition of this pathway in BM-MSC demonstrated the expression of SMCs specific 
genes such as α-SMA, SM22, Calponin and Smoothelin and associated proteins. This 
study also showed that BM-MSC have the capability of expressing elastin a pivotal ECM 
protein for vascular regeneration. Further, this group showed that PDGF-BB inhibits 
SMCs specific gene expression in BM-MSC39. 
Wu et. al.47 investigated the effects of graft material on BM-MNC differentiation 
into SMCs and the quantity and quality of ECM production. Four different types of 
scaffolds – poly(lacticide-co-glycolide), poly(glycerol sebacate) (PGS), PGS coated with 
platelet poor plasma and PGS coated with platelet rich plasma, were studied. After 21 
days of BM-MNC culture in a bioreactor on these substrates, SMC-specific gene 
expression and protein production was assessed. The platelet-rich PGS showed 
significantly increased cell proliferation and insoluble elastin content when compared 
with the other scaffolds. The collagen content remained the same among all four 
constructs as well as the expression and production of SMCs specific genes and proteins 
such as Calponin and α-SMA. Their study demonstrated the guidance of BM-MNC into a 
SMCs phenotype with characteristic ECM production, namely elastin by mechanical 
properties of the scaffold47. 
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 Gong and Niklason48 studied the ability of human BM-MSCs (hBM-MSCs) to 
differentiate into SMCs in both a two dimensional and three-dimensional environment 
using several experiments. For the 2-D cultures, hBM-MSCs were grown on tissue 
culture plastic using several experimental conditions - addition of TGF-β1 and PDGF-BB 
in various concentrations to culture medium; use of treated 6-well plates coated with 
collagen types I, IV, elastin, fibronectin and laminin and subjection to cyclic strain. For 
the 3-D cultures, hBM-MSC were conditioned with growth factors and seeded on PGA 
scaffolds in a bioreactor to form an artificial blood vessel. SMCs differentiation was 
assessed for tissues cultured in the 2-D environment whereas ECM proteins such as 
collagen and elastin were investigated via Massaon Trichrome and Movat histology 
staining in tissues form the 3-D vessel. In the presence of TGF-β1, 2-D cultures showed 
increased expression of a-SMA, Calponin but not SMMHC indicating an immature 
SMCs state. PDGF-BB treated cells showed reduced expression of the same proteins. 
None of the matrix proteins coated on the 6-well culture plate had an effect on hBM-
MSC proliferation and no difference was found between groups for α-SMA expression. 
The 3-D cultures did not reveal positive staining for elastin via the Movat stain nor 
tropoelastin monomers were found via Western blots. The results of this study suggest a 
partial differentiation of hBM-MSC to SMCs and therefore the lack of elastin or its 
monomer48.  
In an in vivo study, Sata et. al.49 demonstrated the contribution of BM-MSC 
recruited after vascular injury to the atherosclerotic lesion. Specifically, they 
demonstrated that BM-MSC undergo differentiation in to a SMCs-like phenotype and 
produce ECM proteins including elastic lamellae.  
  43 
2.8 Characterization of bone marrow mesenchymal stem cell derived smooth muscle 
cells 
Successful differentiation of BM-MSC into SMCs has been monitored through 
the expression of genes for vascular SMCs cytoskeletal and contractile proteins. The 
most frequently examined are smooth muscle alpha actin (α-SMA), calponin, smoothelin, 
SM22α and smooth muscle myosin heavy chain (SMMHC) isoforms21. In the developing 
phenotype of SMCs, α-SMA is considered an early SMCs marker, calponin, smoothelin, 
SM22α are considered mid-stage markers and SMMHC is a late or mature SMCs 
marker21,32. 
α-SMA is one of six isoactins, which are products of separate genes with high 
degree of homology, expressed in mammalian cells. It is the most abundant of the actin 
isoforms in mature fully differentiated vascular SMCs and contributes to 40% of total cell 
protein. Vascular SMCs have the capability of generating the necessary	   force for 
contraction because of this cytoskeletal protein. Smooth muscle α-actin is also the first 
known marker expressed in differentiated SMCs during vasculogenesis and is the protein 
that can be detected the earliest. As vascular tissue develops, α-SMA is expressed at 
increasing levels by vascular SMCs. The expression of this protein is not limited to 
vascular SMCs because it can be expressed transiently by a variety of mesodermally 
derived cells such as cardiac and skeletal myocytes as well as myofibroblasts. Therefore, 
α-SMA alone is not an indicator of SMC differentiation32. 
Calponin is a 28 to 34 kilo Dalton protein that interacts with f-actin and 
tropomyosin in the absence of Ca2+ and with calmodulin in the presence of Ca2+. It also 
inhibits actin-activated Mg2+-ATPase activity of myosin regulating the contraction of 
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vascular SMCs. SM-22α is a 22-kilo Dalton protein containing sequence motif 
homologous to calponin but is not associated with the contractile machinery of SMCs. In 
adult organisms, this protein is exclusively found in SMCs. Calponin has been detected 
relatively late in the development of the organism32. 
SMMHC is an essential component of the contractile machinery and shows a high 
degree of specificity in both mature and developing organisms. This protein is highly 
specific to SMCs and therefore its detection shows a great degree of differentiation 
toward SMCs and commitment to a SMC lineage32. 
The characterization of SMC-specific cytoskeletal markers is done using multiple 
methods. Real time polymerase chain reaction (RT-PCR) detects mRNA for the SMC 
specific proteins described above suggesting SMCs specific gene expression. Western 
Blots detects the presence of SMCs specific proteins suggesting that the mRNA 
transcribed was translated. Immunolabeling with antibodies specific for SMC proteins 
allow the visualization of these markers. 
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CHAPTER III 
METHODS
All experiments of differentiation were based on the work done by Ross J.J. et al33 
and Breyer A. et al 50. 
3.1 Rat bone marrow mesenchymal stem cells (BM-MSCs) culture 
BM-MSCs culture. Passage four mesenchymal stem cells (MSC) (1.0 × 106 cells) 
isolated from the bone marrows of adult Sprague Dawley (SD) rats, were purchased from 
Invitrogen (Carlsbad, CA). These cryopreserved cells were propagated and passaged in 
accordance with the protocol shipped by Invitrogen using rat MSC growth medium 
containing D-MEM low glucose medium, 10% v/v MSC-qualified fetal bovine serum 
(FBS) (Invitrogen), and 1% v/v antibiotic antimycotic solution (Fisher Scientific, 
Hampton, NH). The thawed cells were transferred from the cryovial to a 50-mL sterile 
tube. Pre-warmed MSC growth medium (10 mL) was added dropwise while swirling the 
tube to mix. The cell suspension was centrifuged for 5 minutes at 300 × g, the 
supernatant aspirated, and the cell pellet re-suspended in 5 mL of rat MSC growth 
medium. A 100 µL aliquot of the cell suspension was mixed with an equal volume of 
Trypan Blue, which is taken up by non-viable cells, and counted on a hemocytomer, to 
asses viability. Four T-75 flasks were then seeded at a density of 2.25 × 105 cells per 
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flask (area of 75 cm2) and cultured in rat MSC growth medium at 37 °C for 24 hours. The 
medium was replaced after 24 hours and every two days thereafter for up to five days. 
The cells were then detached from the substrate with 5mL of trypsin added per flask, and 
incubated for 5 minutes at 37 °C, mixed with fresh medium prior to centrifugation (1000 
× g, 10 minutes) to pellet cell. After aspirating off the supernatant, the cell pellet was 
gently pipetted to generate a homogenous suspension. Using a hemocytometer the cell 
viability and total cell count was determined as described above. One million cells per 
vial were cryopreserved using freezing media containing 60% v/v D-MEM low glucose 
medium, 30% v/v MSC-qualified FBS and 10% v/v dimethyl sulfoxide (DMSO; 
Invitrogen) as described by the protocol from the company. 
 
Differentiation of rat BM-MSCs into SMCs and their propagation. Cryopreserved 
passage 5 BM-MSCs were thawed in a 37 °C water bath and centrifuged at 300 × g.  
They were then seeded on six commercially purchased human fibronectin (hFN, 100 
ng/mL)-coated 25 cm2 tissue culture plastic flasks (T-25) (BD Biosciences, East 
Rutherford, NJ) at a density of 3 × 103 cells/cm2 in 5 mL of differentiation medium 
containing components listed in Table 3.1.  
Component Volume (mL) Final Concentration 
DMEM-low glucose 281.66112 60% v/v 
MCDB-201 187.77408 40% v/v 
FBS 10 2% v/v 
Penicillin-streptomycin 5 1% v/v 
ITS 5 1 ×  
LA-BSA 5 1 ×  
Ascorbic Acid (0.01M) 5 10-4M 
Dexamethasone (20µg/mL) 0.0098 10-9 M 
EGF (1mg/mL) 0.005 10 ng/mL 
PDGF-BB (100µg/mL) 0.05 10 ng/mL 
LIF (106 units/mL) 0.5 103units/mL 
Table 3.1 Components of the medium used to differentiate BM-MSCs into SMCs and their individual 
concentrations and volumes. 
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Passage 4 rat aortic smooth muscle cells (SMCs) and BM-MSCs were seeded 
with the same density on four other uncoated T-25 flasks as positive and negative control 
cell types for assessment of differentiation of the BM-MSCs. DMEM-F12 medium 
containing 10% v/v FBS (Hyclone, Waltham, MA) and 1% v/v antibiotic antimycotic 
solution (Medium A) was used to culture SMCs and D-MEM low glucose medium 
containing 10% v/v MSC-qualified FBS and 1% v/v antibiotic antimycotic solution 
(Medium B) was used to culture the BM-MSCs. Cells in all ten experimental cases 
(Table 3.2) were conditioned for 24 hours with the respective media types as described 
earlier.  
Cell Type Medium Substrate  Duration of Culture  
Differentiation Phase on T-25 
BM-MSCs Medium B Uncoated 7 day 14 day 
SMC Medium A Uncoated 7 day 14 day 
BM-MSCs +  
No Factors Differentiation media + No factors hFN coated 7 day 14 day 
BM-MSCs +  
PDGF-BB Differentiation media + PDGF-BB (50 ng/mL) hFN coated 7 day 14 day 
BM-MSCs +  
TGF-β1 Differentiation media + TGF-β1 (5 ng/mL) hFN coated 7 day 14 day 
Propagation Phase on T-75 
BM-MSCs Medium B Uncoated 7 day 
SMCs Medium A Uncoated 7 day 
BM-MSCs +  
No Factors Medium A + No Factors Uncoated 7 day 
BM-MSCs +  
PDGF-BB Medium A + PDGF-BB (50 ng/mL) Uncoated 7 day 
BM-MSCs +  
TGF-β1 Medium A + TGF-β1 (5 ng/mL) Uncoated 7 day 
Table 3.2 Summary of the differentiation and expansion experiments, treatment conditions, growth 
substrate, medium used and duration of cell culture. 
 
The BM-MSCs cultured on hFN coated T-25 flasks were differentiated for 7 and 
14 days in the above differentiation medium in the presence of exogenous platelet 
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derived growth factor BB (PDGF-BB; 50 ng/mL; R & D Systems, Minniapolis, MN) and 
transforming growth factor β1 (TGF-β1; 5 ng/mL; Peprotech, Rocky Hill, NJ) or in their 
absence.  The control cell types were cultured for the same period with the prior specified 
respective medium types. During the 7 or 14 day period of differentiation or culture, 
spent medium was exchanged for fresh pre-warmed medium along with growth factors 
where applicable, every two or three days. At the end of each designated period of 
differentiation, the cells were trypsinized, divided into three equal aliquots, and re-seeded 
into three uncoated T-75 culture flasks for further propagation. Growth factors where 
applicable were added with Medium A for SMCs and differentiated BM-MSCs whereas 
the BM-MSCs control was treated with the same media used in the differentiation culture 
period (Medium B). Media was changed every two to three days. 
 
Cell culture harvest. After expanding the differentiated cells over a further of 7 days, 
each group of cells were trypsinized, and the cell viability and total cell count determined 
in each case. Sterile tissue culture 6-well plates (area of 9.6 cm2) were seeded with the 
harvested cells at a density of 3 × 104 cells/well and cultured for 21 days for phenotypic 
analysis and ECM characterization respectively.  
Figure 3.1 summarizes the methodology used for the differentiation, propagation 
and biochemical experiments. 
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Figure 3.1 Schematic of the differentiation, expansion and biochemical experiments. 
 
3.2 Immunofluorescence –based detection of phenotypic cell markers 
Cell culture. After the expansion phase, BM-MSCs that had been cultured with and 
without differentiated growth factors for 7 and 14 days, and BM-MSCs and SMCs 
cultured for 7 and 14 days were trypsinized and seeded at a density of 3 × 104 cells on 
sterile glass cover slips (area of 7.2 cm2; Fisher Scientific) placed within 6-well plates. 
Medium A was used to culture SMC and differentiated BM-MSCs, while Medium B was 
used to culture the BM-MSCs (control cell type). Cells were cultured for 7 days with 
medium changes every 2-3 days.  
Sample preparation. After 7 days of culture, the spent culture medium was carefully 
aspirated from each cell layer and cells fixed with 4% v/v EM-grade paraformaldehyde 
(Polysciences Inc., Warrington, PA) diluted in 1× PBS (25 °C, 15 minutes). The fixative 
was then removed, the cell layer gently rinsed with 1× PBS (3 cycles), and blocked and 
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permeabilized with PBS (1×) containing 3% v/v goat serum (VWR, Radnor, PA), 0.3% 
v/v Triton-100X detergent (25 °C; Sigma-Alderich, St. Louis, MO). Prior to use, 
processing solutions were filtered using a 0.22μm vacuum filter to sterilize and remove 
any debris that may contribute to background in the staining process. Primary antibodies 
purchased from Abcam (Cambridge, MA) were diluted in the blocking and 
permeabilization buffer according to the concentrations determined via prior titration 
experiments (Table 3.3).  
Primary antibody Host Concentration (v/v) Clonality 
Smooth muscle alpha actin (αSMA) Rabbit 1:500 polyclonal 
Calponin Rabbit 1:500 monoclonal 
Smooth muscle 22 alpha (SM22-α) Rabbit 1:100 polyclonal 
Smooth muscle myosin heavy chain 
(SMMHC) Rabbit 1:50 polyclonal 
Table 3.3 Summary of primary antibody concentrations used for immunoflourescence. 
 
Antibody labeling was conducted in a humidity chamber. Diluted primary 
antibody solution (250 μL) was carefully added to cover the entire surface of each cell 
layer for each treatment condition and cell type. An equal volume of blocking and 
permeabilization buffer was added to one cell layer for each treatment as a negative 
immunolabeling control. Primary antibody labeling was conducted overnight at 4 °C.  
Following this, the primary antibody solution was pipetted off, the cell layers rinsed with 
1× PBS (3 cycles) and then incubated (37 °C, 1 hour, dark) with solutions containing 
secondary antibodies conjugated with Alexafluor 594 (Invitrogen), a donkey-anti-rabbit 
immunoglobulin (λexcitation = 590 nm and λemission = 617 nm) diluted in the blocking and 
permeabilization buffer at a concentration of 1:1000. Finally, the cell layers were rinsed 
with 1 × PBS (25 °C, 3 cycles) and then mounted onto glass microscope slides with 
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Vecta shield mounting medium containing the nuclear dye DAPI (Vector Laboratories, 
Burlingame, CA). The mounted slides were blotted on paper towels for 30 minutes and 
once dried, sealed with nail polish on the edges of the glass cover slips.  
 
Qualitative analysis. Composite images for cells labeled with fluorescent antibodies were 
obtained using a phase contrast Leica DMR upright fluorescence microscope (Leica 
Microsystem, Buffalo Grove, IL) and imaged with an attached digital CCD camera 
(Princeton Instruments, Acton, MA) set to Texas red to visualize intracellular SMC 
specific proteins such as α-SMA, Calponin and SM22-α. The DAPI-stained nuclei were 
visualized via an Ultraviolet laser and blue filter. For each primary antibody, at least n ≥ 
3 images were obtained after scanning the entire slide and identifying areas with the 
greatest density of cells and staining. The exposure time, gain, offset and gamma settings 
were chosen based on an initial qualitative comparison of antibody staining among SMC 
positive control, BM-MSCs treated with NF, PDGF-BB and TGF-β1. The settings were 
consistent for all experimental conditions for each primary antibody. All 
immunofluorescence images for BM-MSCs treated with or without growth factors (NF, 
PDGF-BB and TGF-β1) were obtained at 40× magnifications whereas those for SMCs 
were obtained at 10×. 
 
Quantitative analysis. For quantitative analysis of the immunofluorescence results, 
images taken with the same parameters for qualitative analysis were saved in a separate 
folder with images for the nuclei (DAPI) and antibodies of interest as separate file names. 
The saved images were analyzed with ImagePro® software (Media Cybernetics, 
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Inc., Bethesda, MD) for four measurements: 1) average area of fluorescence in the field 
of view (FOV), 2) the average density or intensity of staining in the FOV, 3) percent area 
(per area) – a ratio of the average area stained to the total area in the FOV and 4) nuclei 
count – the total number of cells in the FOV. The software measured all four parameters 
based on the number of ‘objects’ it counted per image. An object is defined as any 
continuous group of pixels positive for the desired parameter and object number in 
ImagePro® does not equal cell number. Percent area measures the ratio of the area sum of 
objects and total area sum of the image. Statistics such as mean, standard deviation, 
minimum and maximum values were collected using the ImagePro® software.  
3.3 Flow cytometry 
BM-MSCs, SMCs and BM-MSCs differentiated over 7 and 14 days, were 
expanded for 7 days and analyzed by flow cytometry (FC) for extent of expression of 
BM-MSC surface markers as well as SMC-specific intracellular markers (Table 3.4). All 
antibodies were purchased either pre-conjugated with a secondary fluorophore or with a 
conjugation kit and were first titrated with a positively staining cell type to determine 
optimal working volumes for each (Table 3.4). 
 
Ab Function 
Pre-
conjugated 
fluorophore 
Host 
Working 
volumes 
(µL) 
Excitation 
(nm) 
Emission 
(nm) Source 
BM-MSC surface markers 
CD 29 Integrin β1 protein 
Alexa Fluor 
488 
Hamster 
(IgG) 1 488 519 
BioLegend, 
San Diego, 
CA 
CD 90 Thymocyte-1 antigen 
Brilliant 
Violet 421 
Mouse 
(IgG1) 1 405 421 
BioLegend, 
San Diego, 
CA 
SMC intracellular markers αSMA Contractile protein FITC Mouse (monoclonal) 2.5 492 520 Abcam, Cambridge, MA 
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Ab Function 
Pre-
conjugated 
fluorophore 
Host 
Working 
volumes 
(µL) 
Excitation 
(nm) 
Emission 
(nm) Source 
SM22-α SMC-specific cell shape 
protein 
PE-Cy7 
(Lightning-
Link PE-Cy7 
antibody 
labeling kit) 
Primary 
antibody -
Goat 
(polyclonal) 
1.28 565 767 
1°Ab: Abcam, 
Cambridge, 
MA 
Conjugation 
kit: Novus, 
Littleton, CO 
SMMHC 
Contractile 
structural 
protein 
Alexa Fluor 
647 
Mouse 
(IgG1) 1.25 633 668 
eBioscience, 
San Diego, 
CA 
Table 3.4 Flow Cytometry antibodies used to analyze the extent of BM-MSC and SMC specific markers. 
 
Cells from each treatment condition after the propagation phase were detached 
using trypsin and centrifuged (600 × g, 8 minutes, 25 °C) to pellet the cells. The 
supernatant was aspirated and the cell pellet was re-suspended in 10 mL of 1× PBS with 
1% w/v bovine serum albumin (BSA), re-centrifuged, resuspended in 10 mL of 1× PBS 
with 1% v/v BSA, and incubated (25 °C, 15 minutes). A count was performed for viable 
cells and 1 × 105 cells were dispensed per eppendorf tube per treatment condition. 
Additional tubes with BM-MSCs and SMCs (1 × 105 cells per tube) were included in the 
experiment for calibrating the flow cytometer and setting up a baseline for gating and 
data analysis (unstained – no antibody and single-stain – BM-MSCs or SMCs positively 
stained with one antibody of interest). The cell suspension was then centrifuged (10000 × 
g, 15 seconds) and the supernatant aspirated. The cell pellet was washed by gently mixing 
the cell suspension in 800μL of FACS buffer containing 1× PBS, 25 mM HEPES 
(Fisher), 1% w/v BSA, 0.02% w/v NaN3 and 0.5 mM EDTA (Amresco, Solon, OH). The 
cell suspension was then re-centrifuged (10000 × g, 15 seconds) and the supernatant 
removed. A cocktail of antibodies for BM-MSC surface markers (Table 3.5) exceeding 
100 μL was prepared by diluting them in FACS buffer. BM-MSC control cell types as 
well as BM-MSCs differentiated with an without growth factors were incubated (25 °C, 
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15 minutes, in the dark) with the surface antibody cocktail. The cells were washed twice 
with 800 μL of FACS buffer and centrifuged (10000 × g, 15 seconds) and the supernatant 
aspirated.  
Cell Type and 
Test condition 
CD 29 
(µL) 
CD 90 
(µL) 
aSMA 
(µL) 
SM22-α 
(µL) 
SMMHC 
(µL)  
FACS 
buffer 
(µL)  
Perm 
buffer 
(µL)  
BM-MSCs 
unstained 0 0 0 0 0 80 0 
BM-MSCs 
CD 29 1 0 0 0 0 79 0 
BM-MSCs 
CD 90 0 1 0 0 0 79 0 
SMCs 
unstained 0 0 0 0 0 0 80 
SMC 
αSMA 0 0 2.5 0 0 0 77.5 
SMC 
SM22-α 0 0 0 1.28 0 0 78.72 
SMC 
SMMHC 0 0 0 0 1.25 0 78.75 
BM-MSCs 1 1 2.5 1.28 1.25 78 74.97 
SMC 1 1 2.5 1.28 1.25 78 74.97 
BM-MSCs + NF 1 1 2.5 1.28 1.25 78 74.97 
BM-MSCs + 
PDGF-BB 1 1 2.5 1.28 1.25 78 74.97 
BM-MSCs + TGF-
β1 1 1 2.5 1.28 1.25 78 74.97 
Table 3.5 Summary of unstained, single stain and test samples including buffer volumes and antibodies.  
 
In order to stain for SMC specific intracellular proteins, SMCs and BM-MSCs 
differentiated with and without growth factors cell pellets were then suspended in 100 μL 
of IC Fixation buffer (eBioscience, San Diego, CA) and incubated (25 °C, 20 minutes, in 
the dark). Meanwhile, to prepare an intracellular antibody cocktail (Table 3.5), the SMC 
specific antibodies were diluted in 1× permeabilization buffer (eBioscience, San Diego, 
CA) to a total volume (antibody + buffer) less than 100 µL. Fixed cell pellets were 
permeabilized by mixing with 1 × permeabilization buffer (150 µL), the cell suspension 
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centrifuged to re-pellet cells and supernatant aspirated. Cell pellets were re-suspensed in 
1× permeabilization buffer (150 µL) and re-centrifuged and supernatant aspirated. The 
resulting cell pellets were incubated (25 °C, 15 minutes, in the dark) with the intracellular 
antibody cocktail. The antibody cocktail was diluted with 1 × permeabilization buffer 
(150 µL), re-centrifuged and supernatant aspirated. Cells were washed with 150 µL of 
each 1 × permeabilization buffer (2 cycles) and FACS buffer (2 cycles). The cells 
suspensions were re-centrifuged, re-suspended in FACS buffer (150 µL) and filtered with 
a polystyrene tube with 40 µm cell strainer cap. Ms. Cathy Shemo from the Flow Core at 
The Lerner Research Institute then analyzed the samples with a flow cytometer. 	  
Gating and analysis. Data collected from the flow cytometer was analyzed using a 
software package called FlowJo®. Based on the unstained and single-stain control data, 
gating for each antibody was performed on the experimental data. Gating is a process of 
eliminating results from unwanted particles (dead cells, debris) and selectively visualize 
cells of interest. A single parameter histogram was plotted to highlight the relative 
fluorescence intensity (x-axis) against the number of events (cells, y-axis) for each 
antibody by Ms. Anne Cotleur from the Flow Core at The Lerner Research Institute. 
3.4 Cell cycle analysis 
Cell cycle profiles of BM-MSCs, BM-MSCs derived cell populations (in the 
presence and absence of growth factors), and SMCs were compared to confirm that 
differentiation culture protocols indeed generated SMC-like cells and to compare 
differentiation outcomes between 7 and 14 day time points. The cell lines were trypsinzed 
at 80% confluence and enucleated by suspending in a buffer containing detergent (NP-
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40), RNAse, and Propidium iodide (PI; Vindelov’s reagent; Invitrogen). After incubation  
for two hours, cell cycle analysis of the cell layers were generated using Accuri® C6 flow 
cytometer (BD Biosciences) and further comparative analysis was performed using  
FCSExpress® analysis software (De Novo Software, Los Angeles, CA).  
3.5 RT-PCR for gene expression changes 
Cell culture. BM-MSCs cells differentiated with and without factors for 7 and 14 days, 
BM-MSCs and SMC cultured for 7 and 14 days, were expanded for 7 days, then 
trypsinized and seeded at a density of 3 × 104 cells per well of 6-well plates (area = 9.6 
cm2). Medium A (for SMCs and differentiated BM-MSCs) or Medium B (for control type 
BM-MSCs) was added to each well, and the respective cells were cultured for 21 days, 
with medium changes every 3 days. 
 
RNA isolation. After 21 days of culture, cells were harvested, and total RNA was 
isolated using the RNeasy kit (Qiagen, Valencia, CA) at 25 °C. The cell layer was 
disrupted from each 6-well plate by adding 600 μL of RLT buffer (a guanidine thymocyte 
buffer) and 600 μL of 70% v/v RNase free ethanol, and scraping off. Each lysed sample 
was homogenized by gentle mixing with a micropipette and transferred to an RNeasy 
column. The RNeasy column was centrifuged (3 cycles, 8000 × g, 15 seconds, 25 °C) 
with RLT buffer (600 µL), RW1 buffer (700 μL) and RPE buffer (500 μL) added 
respectively prior to each centrifugation cycle and the flow-through discarded. The 
RNeasy column was centrifuged at the highest possible speed for 1 minute and then 
moved to a new 1.5 mL tube. RNase free water (30 μL) was added and re-centrifuged 
(8000 × g, 1 minute).  
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RNA quantification. The isolated RNA was quantified using a Quanti-iTTM RiboGreen© 
RNA Reagent Kit (Invitrogen), an ultrasensitive fluorescent nucleic acid stain for 
quantifying RNA in solution. TE Buffer (1×; 10 mM Tris-HCL, 1 mM EDTA, pH 7.5) 
prepared in nuclease-free water was used to dilute the RiboGreen© reagent, RNA 
standard stock solution and RNA isolated from test cell cultures. The RiboGreen© reagent 
was warmed (25 °C) and an aqueous working solution was prepared by diluting dye stock 
in 1× TE buffer to prepare a dilution of 1:200. To generate an RNA standard curve, a 2 μg/mL stock solution was prepared by diluting 20 μL of RNA stock (100 μg/mL) in 980 μL of 1× TE buffer (a dilution of 1:50). The standard stock solution (200 μL) was 
pipetted into a 96-well plate in duplicates and serially diluted by adding 1× TE buffer 
(100 μL). For the experimental samples, 2 μL of RNA isolate was diluted in 98 μL of 1× 
TE buffer and added to the same 96 well plate in duplicates. Diluted RiboGreen© dye 
(100 μL) was added to all wells containing RNA sample or RNA stock solutions. The 
sample fluorescence was measured using a spectrofluorometer set for λexcitation = 488 nm 
and λemission = 525 nm. The volumes of the sample RNA solutions were adjusted such that 
a target amount of 1000 ng of RNA per sample was obtained. In addition to the volumes 
of RNA, volumes of nuclease free water were calculated to achieve a total volume of 15 μL of RNA plus water for complementary DNA (cDNA) reverse transcription. 
 
cDNA transcription and isolation. cDNA from the RNA elute was isolated and extracted 
using iScript™ cDNA synthesis kit (Bio-rad, Hercules, CA) that contains three 
components: a reaction mix with deoxyribonucleotides and hexamers that serve as 
primers,  reverse transcriptase enzyme and nuclease free water.  To prepare 20 μL of 
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cDNA per experimental sample, 15 µL of RNA isolate, 4 µL of reaction mix and 1 µL of 
reverse transcriptase enzyme were mixed together in a nuclease-free PCR plate. The PCR 
plate was incubated in a thermocycler set at different temperatures for several periods to 
assist the reactions in producing cDNA (25 °C, 5 minutes; 42 °C, 30 minutes; 85 °C, 5 
minutes and held at 4 °C). The cDNA samples were diluted 3 times with nuclease free 
water stored at -20°C.  
 
RT-PCR sample preparation and reaction. Gene expression was quantified by a real 
time polymerase reaction performed in an ABI PRISM 7000 system (Applied 
Biosystems, Foster City, CA) using SYBR® green master mix (Applied Biosystems) and 
primer sets previously optimized in our lab for SMCs.  PRC plates for genes encoding for αSMA, Caldesmon, SMMHC, tropoelastin, LOX and 18S (housekeeping gene), were 
prepared for amplification. The reaction mix was prepared such that a total volume of 20 μL was not exceeded (10 µL of 2× SYBR® green master mix, 3 µL of cDNA, 2 µL of 
primer and 5 µL of nuclease-free water) in triplicates. Two controls – no template control 
(0 µL of cDNA, 8 µL of nuclease-free water) and RNA control (3 µL of RNA, 5 µL of 
nuclease-free water) was also prepared in triplicates. 
 
Data analysis. RT-PCR data was analyzed using the 2-ΔΔCT method, a relative 
quantification technique that describes the change in the expression of a target gene 
relative to a control. CT stands for the threshold cycle and indicates the partial cycle 
number at which the amount of amplified gene reaches the fixed threshold. The CT values 
generated by the RT-PCR machine were then analyzed by the 2-ΔΔCT method51. RT-PCR 
  59 
for 18S, a housekeeping gene was performed and was used to normalize all CT values 
obtained for the genes in question per treatment condition giving the ΔCT value. The ΔCT 
values were averaged and subtracted from ΔCT values of SMCs (positive control) to give 
the ΔΔCT value. To obtain the fold change, the ΔΔCT value was multiplied by -1 and was 
used as the exponent of 2 to give the 2-ΔΔCT values. 
3.6 DNA assay for cell proliferation 
Cell culture and harvest. BM-MSCs differentiated with and without factors for 7 and 14 
days, BM-MSCs and SMCs cultured for 7 and 14 days were expanded further for  days, 
then trypsinized and seeded at a density of 3 × 104 cells per well of 6-well plates (area = 
9.6 cm2). Medium A (for SMCs and differentiated BM-MSCs) or Medium B was added to 
each well. The cells were cultured for 21 days with medium changes every 3 days and 
harvested in 3mL Pi Buffer (50 mM Na2HPO4, 2 mM EDTA, 0.02% w/v NaN3). The cell 
suspensions were sonicated on ice and 300 μL was aliquoted for DNA assay and the 
remaining 2.7 mL was stored (-20 °C) for fastin and hydroxyproline assay.  
 
Sample preparation. Calf thymus DNA stock solution (100 μg/mL) was diluted in 
NaCl/Pi buffer (4 M NaCl, 50 mM Na2HPO4, 2 mM EDTA, 0.02% NaN3) tenfold and 
used to obtain a standard curve. In an opaque 96-well plate, 200 μL of DNA stock 
solution was added to duplicate wells and serially diluted in Pi buffer using a multi-
channel pipette. To other wells of the 96-well plate, 98 μL of Pi buffer and 2 μL of test 
cell culture DNA was added. Bisbenzimide (Hoechst 33258; Invitrogen) dye stock 
solution (0.2 mg/mL) was diluted (1:100) in NaCl/Pi buffer. The diluted dye solution 
(100 µL) was distributed to wells with samples, incubated (25 °C, 30 minutes, in the 
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dark) and the sample fluorescence was measured using a spectrofluorometer set for 
λexcitation = 356 nm and λemission = 525 nm. The cell density in test and treatment cell layers 
was calculated based on an estimate of 6 pg DNA/cell52.  
3.7 Fastin assay for elastin quantification 
Sample preparation. The amounts of matrix elastin (alkali-soluble and insoluble 
fractions) were quantified using a Fastin assay (Biocolor Ltd. Carrickfergus, County 
Antrim, UK). The sonicated cell culture samples stored in -20 °C (section 3.6) were 
thawed (37 °C) and divided into two tubes for each treatment condition (800 μL per 
tube). An equal volume of 0.1 M NaOH was added to the cell suspension and heated for 
1 hour. Each sample was then centrifuged (12000 rpm, 10 minutes) and the supernatant 
divided equally – one aliquot for the hydroxyproline assay and one for the Fastin assay 
for soluble elastin. The supernatants and cell pellets were stored at -20 °C for further 
biochemical processing.  
The cell pellets were thawed, mixed with 0.25 M oxalic acid (250 μL), heated for 
1 hour, centrifuged (12000 rpm, 10 minutes), the supernatant transferred to centrifugal 
filter columns which were centrifuged (12000 rpm, 10 minutes) and the flow-through 
discarded. Insoluble elastin was released into collection tubes by centrifuging (8000 rpm, 
15 seconds) inverted filter columns into new tubes and further diluted using 0.25 M 
oxalic acid (200 μL).  
 
Alkali-soluble and insoluble elastin assay. The assay was performed on duplicate test 
samples, elastin standards and reagent blanks. Elastin standards (0, 12.5, 25, 50	  and	  100	  μL) mixed with 0.25 M oxalic acid (total volume per standard = 100 μL) were prepared.  
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Elastin from all the samples (cell pellets, supernatants, standards) was recovered 
by the addition of equal volume of elastin precipitating reagent (Biocolor Ltd. 
Carrickfergus, County Antrim, UK), incubation (25 °C, 10 minutes), concentration of 
precipitate by centrifugation (10000 × g, 10 minutes) and discarding the supernatant. Any 
remaining fluid was removed by forceful tapping onto absorbent paper towels and water 
droplets removed with a Q-tip. Samples were then incubated (25 °C, 90 minutes) with 
Fastin dye reagent (500 μL; Biocolor Ltd.) while simultaneously being vortexed and 
mechanically mixed to bring the sample precipitate into solution. The resulting insoluble 
elastin-dye complex (due to ammonium sulfate in the dye reagent) was separated from 
unbound dye by centrifugation (10000 × g, 10 minutes) and the supernatants discarded. 
Any remaining fluid was removed by forceful tapping onto absorbent paper towels and 
water droplets removed with a Q-tip. The elastin-dye complex was brought into solution 
by adding a dye dissociation reagent (250 μL; Biocolor Ltd.) and briefly mixing the 
contents with a vortex mixer. Samples were then transferred into an opaque 96-well plate 
and the absorbance measured using a spectrofluorometer set for λabsorbance = 513 nm. The 
measured elastin amounts were normalized to corresponding DNA amounts to provide a 
reliable basis of comparison between samples. 
3.8 Hydroxyproline assay for collagen quantification 
Sample preparation. A Hydroxy-proline (OH-Pro) assay was used to estimate collagen 
content within BM-MSC cultures differentiated with and without growth factors for 7 and 
14 days, SMC and BM-MSC controls. The samples (digestates from section 3.7) were 
hydrolyzed in duplicates (115 °C, 16 hours) with 6 N HCl (800 μL) per test condition and 
then cooled (25 °C).  
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Determination of OH-Pro content. The samples were then placed in a heater block (37 °C) in two batches and HCl evaporated under a stream of nitrogen directed into each via a 
silicone capillary tubing. Each hydrolyzate dissolved in de-ionized water (100 μL) as 
well as collagen standard solutions (0, 10, 25, 50, 100, 150, 300 μg/mL) were placed into 
duplicate glass tubes (40 μL of sample per tube). The samples and standards were 
vortexed with Chloramine-T reagent (250 μL), incubated (25 °C, 20 minutes), briefly 
vortexed and incubated (60 °C, 15 minutes) again with Perchloric acid (250 μL). The 
samples were aliquoted into duplicate wells of an opaque 96-well plate (250 µL) after a 
final vortexing and the absorbance measured using a spectrofluorometer set for λabsorbance 
= 558 nm. The matrix collagen amounts in the samples were calculated based on the 
coefficients obtained from the standard curve, and normalized to DNA content of 
corresponding cell layers. 
3.9 LOX activity assay 
Sample preparation. Lysyl oxidase (LOX) is an endogenous enzyme that crosslinks 
tropoelastin, thereby making it insoluble. Estimating the activity of this enzyme in the 
ECM and therefore culture medium is an indirect measure of cell-mediated crosslinking 
of elastin within cell layers to form mature matrices. Therefore, spent culture medium 
aliquots from the 21-day cell culture period of BM-MSCs differentiated with and without 
growth factors for 7 and 14 days, SMC and BM-MSC control cultures were collected and 
pooled during each medium change stored at -20 °C prior to the LOX activity assay.  
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Determining LOX protein synthesis. The media samples were assayed for LOX activity 
using a flurometric assay (Amplex® Red Assay, Molecular Probes, Eugene, OR) based on 
measurement of H2O2 released when LOX oxidatively deaminates alkyl monoamines and 
diamines52. Briefly, two buffers were prepared with the reaction buffer (1×) provided by 
the assay – 1) horseradish peroxidase (HRP) solution (0.2 U/mL), 2) 1.2 M urea, 10 mM 
diaminopentane and HRP (50 μL). The Amplex® Red dye was reconstituted (10 mM) 
with DMSO (60 μL) of DMSO and added to the buffers. Peroxide standards (0,10, 20, 
30, 40, and 50 μL) were prepared according to the manufacturer’s protocol. To an opaque 
96-well plate, peroxide standards and media samples were added with buffers such that 
the total volume per well equal 100 μL. Additionally, to half of the media sample wells 
the buffer with diaminopentane and to the others, buffer no diaminopentane was added. 
The plate was incubated (37 °C, 30 minutes) and the absorbance measured using a 
spectrofluorometer set for λabsorbance = 560 nm. Amounts of peroxide were calculated 
based on the coefficients obtained from the standard curve.  
3.10 Statistical analysis 
Comparisons between the BM-MSCs differentiated in the presence and absence 
of growth factors, BM-MSCs, and SMCs were analyzed using the Student’s t-test. 
Statistical significance was deemed for p < 0.05. Data are shown as mean with ± standard 
error with symbols in figures denoting statistical significance (p < 0.05) for groups 
compared with SMCs, BM-MSCs, and BM-MSCs differentiated without the presence of 
exogenous cytokines.  
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CHAPTER IV 
RESULTS AND DISCUSSION
 
4.1 Introduction 
The following sections of this chapter presents the results obtained from various 
experiments conducted to first demonstrate the impact of growth factor choice and time 
period of differentiation on BM-MSCs in their transformation into SMCs. The 
experiments also assess the quantity and quantity of elastin produced by BM-MSC-
derived SMCs in the presence and absence of growth factors when compared to 
terminally differentiated adult vascular SMCs (positive controls) and undifferentiated 
BM-MSCs (negative control). The materials and methods used to conduct the 
experiments are detailed in Chapter III of this thesis.  
4.2 Immunofluorescence 
BM-MSCs were differentiated in the presence of growth factors (TGF-β1 and 
PDGF-BB) or in their absence (no factors – NF) on tissue culture plastic coated with 
hFN. The control cell types SMCs and BM-MSCs, however, were cultured on uncoated 
tissue culture plastic. Therefore, qualitative and quantitative data on cell expression of 
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cell type specific phenotypic markers obtained via immunofluorescence (IF) was only 
compared among BM-MSCs treated with TGF-β1, PDGF-BB and no growth factors. 
Data obtained from labeling SMCs is presented in this section to demonstrate outcomes 
sought to be achieved by differentiating BM-MSCs and to serve as a	  point of comparison 
for discussion purposes. Results from staining for three of the tested four SMC-specific 
phenotypic markers (αSMA, Calponin and SM22-α) are shown in this section for NF, 
TGF-β1, and PDGF-BB treated BM-MSCs. In all cases, BM-MSC-derived cells did not 
express SMMHC, a late-stage SMC marker, and hence are not shown. 
Qualitative results. Figures 4.1 through 4.4 show qualitatively the average staining per 
culture for each experimental condition demonstrating the positive effects of the three 
growth factors in coaxing differentiation of BM-MSCs towards an SMC phenotype. BM-
MSCs cultured for 7 and 14 days on a non-fibronectin coated substrate did not show 
positive staining for any of the SMC-specific phenotypic markers (data not shown). 
Figure 4.1 shows the staining of SMCs with α-SMA, Calponin and SM22-α. Figure 4.2 
shows a comparison between NF, PDGF-BB and TGF-β1 treated BM-MSCs for staining 
with α-SMA, Figure 4.3 shows a comparison between NF, PDGF-BB and TGF-β1 for 
staining with Calponin and Figure 4.4 shows a comparison between NF, PDGF-BB and 
TGF-β1 for staining with SM22-α. 
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Figure 4.1. Fluorescence images at 10× magnification showing staining of SMCs for α-SMA, Calponin 
and SM22-α (red) following 7 and 14 days of culture on uncoated substrates. DAPI-stained nuclei appear 
blue. 
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Figure 4.2.  Fluorescence images at 40× magnification showing αSMA staining (red) of BM-MSCs 
differentiated with and without growth factors over 7 and 14 days. DAPI-stained nuclei appear blue.  
 
In Figure 4.2, BM-MSCs differentiated with PDGF-BB and TGF-β1 for 7 and 14 
days show positive staining for α-SMA, a conclusive early stage marker of SMCs, 
compared to those with no growth factors, which showed negative staining. These results 
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indicate that the growth factors are essential to coaxing BM-MSCs toward a SMC-like 
phonotype in vitro culture. 
 
Figure 4.3. Fluorescence images at 40× of BM-MSCs differentiated with and without growth factors over 7 
and 14 days stained with Calponin (red), a mid-stage SMC phenotypic marker. DAPI-stained nuclei appear 
in blue. 
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As seen in figure 4.3, BM-MSCs differentiated with PDGF-BB and TGF-β1 
show positive staining for Calponin, a mid-stage SMC marker, while BM-MSCs cultured 
for 7 days on hFN substrates in the absence of any growth factors stained negatively for 
Calponin. While this suggests that the growth factors are essential to differentiate BM-
MSCs into SMC-like cells, the positive staining of 14 day differentiated BM-MSCs (NF) 
for Calponin additionally suggests that the hFN substrate itself is able to coax some 
degree of differentiation of the BM-MSCs although this occurs at more extended culture 
times. These results indicate that the growth factors as well as substrate (hFN) influenced 
BM-MSCs differentiation toward a SMCs-like phonotype in vitro. 
In Figure 4.4 different results are observed. Both BM-MSCs cultured on hFN 
substrates with no factors and those differentiated on the same substrate but with TGF-β1 
over 7 days showed little/no staining. In the case of TGF-β1, the staining appears highly 
diffused and may likely be due to non-specific binding of the primary antibody. At 14 
days of differentiation, the results were different, in that both the NF and growth factor 
treated cultures stained positive for SM22-α though the TGF-β1 treated BM-MSCs 
appeared to have more intense staining. Treatments with PDGF-BB and no factors have 
relatively less intense staining. A greater number of cells appear to stain positive for 
SM22-α in the image with no factor treated BM-MSCs. Thus, while PDGF-BB coaxes 
early expression of SM22-α, the expression levels appear unchanged with increase in 
differentiation time. Together, these results again, suggest a combinatory effect of 
substrate as well as growth factor-induced BM-MSC differentiation toward a SMC-like 
phonotype in vitro. 
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Figure 4.4. Fluorescence images at 40× of BM-MSCs differentiated with and without growth factors for 7 
and 14 days, and then stained with SM22-α (red). DAPI-labeled nuclie appear blue. 
 
Quantitative results. The density/intensity parameter summates the density or intensity of 
fluorescence inside each ‘object’ (cell). Figure 4.5 shows the average density or intensity 
of staining normalized to the total nuclei count obtained in the FOV. The percent area is 
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the ratio of the average area stained (µm2) to the total area (µm2) in the FOV. This ratio 
normalized to the total cell count in the FOV is shown in Figure 4.6.  
 
 
Figure 4.5. Average SMC phenotypic marker staining intensity in BM-MSC cultures differentiated with 
NF, PDGF-BB and TGF-β1 shown normalized to the number of nuclei in FOV. 
 
From Figure 4.5, we deduce that a) in the absence of growth factors, no 
differentiation is initiated at least for 7 days, b) a hFN substrate alone is able to coax 
differentiation to a SMC-like phenotype but only at a possible minimum of 14 days of 
culture, and c) the differentiated cells are highly contractile in expressing the SMC 
marker, SM-22α intensely. The results are not surprising since the basal medium used to 
culture the cells contain low levels of PDGF-BB (Section 3.1). The data also suggests 
that d) additional PDGF-BB provided to supplement basal levels in the serum, does 
hasten early (7 day) differentiation to an SMC phenotype compared to NF conditions, 
although the cells appear to lose this contractile phenotype at longer periods of 
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differentiation (i.e., 14 day). Differently, while TGF-β1, like PDGF-BB, provides early 
stimulus to BM-MSCs toward differentiation into SMC-like cells, the SMC-like 
characteristics of the derived cells are enhanced with differentiation time in that 
expression of both Calponin and its homologue SM22-α are progressively increased. An 
interesting observation was the low levels of α-SMA expression by the BM-MSC-derived 
cells, regardless of substrate presence or absence of growth factors, identity of growth 
factors and differentiation time. Studies have shown that non-vascular SMCs 
predominantly express γ-actin and not α-actin, which is expressed mostly by vascular 
SMCs53. Thus it is possible that our differentiation protocols yield cells that more closely 
resemble non-vascular SMC types. 
 
 
Figure 4.6. Average fractional area of cell fluorescing due to expressed SMC markers, normalized to the 
number of differentiated BM-MSC nuclei in the FOV. The BM-MSCs were differentiated with NF, PDGF-
BB and TGF-β1 over 7 and 14 days. 
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As seen in Figure 4.6, there is no difference among the treatment conditions for 
average percent area of α-SMA staining per cell, which is low across 
treatments/differentiation times. When expressed in terms of fluorescing cell area, trends 
in expression of the SMC markers were maintained between treatments, differentiation 
times, as deduced from Figure 4.5. The area of staining was twice as more in the TGF-β1 
and NF treated BM-MSCs for 14 days compared to the PDGF-BB treated group for the 
same period. Irrespective of treatment group/time, (except for NF for 7 days), the derived 
cells showed greatest expression of SM22-α. The data presented in this manner again 
agree with the inferences made from Figure 4.5.  
The results of quantitative analysis of immunofluorescence data suggest that hFN 
itself may be a good modulator of SMCs-like phenotype.  Also, since the culture medium 
for NF treated BM-MSCs contained a basal amount of PDGF-BB, the data demonstrates 
the influence of basal cytokine levels in the serum in the differentiation process. 
Regardless, our results also indicate that TGF-β1 stimulates earlier differentiation of BM-
MSCs into SMCs, and that these differentiation effects, unlike that induced by PDGF-
BB, are enhanced with duration of differentiation.  
4.3 Flow cytometry 
Flow cytometry results for BM-MSCs differentiated with NF, PDGF-BB and 
TGF-β1 shown as histograms with expression intensities overlaid for comparison 
between treatment groups (Figure 4.7).  
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Figure 4.7. Comparison of the distribution of fluorescence intensities for α-SMA, SMMHC and SM22-α, 
among BM-MSCs differentiated with NF, PDGF-BB and TGF-β1 for 7 and14 days column. 
 
Flow cytometry indicates that BM-MSCs differentiated with TGF-β1, especially 
for 14 days, more intensely express α-SMA than do BM-MSCs differentiated with TGF-
β1 over 7 days, BM-MSC cultured with no factors, or those differentiated with PDGF-
BB. There was no difference in expression of other later-stage SMC-specific phenotypic 
marker proteins (SMMHC, SM22-α) between the treatment conditions, suggesting 
(especially with SMMHC) that terminal differentiation was not approached.  
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4.4 Cell cycle analysis 
Cell cycle analysis profiles for SMCs, BM-MSCs, and BM-MSCs differentiated 
with NF, PDGF-BB and TGF-β1 over 7 and 14 days, were normalized to the peak values 
within the sample and compared. Figure 4.8 shows the comparison of cell cycles and 
Table 4.1 and 4.2 show the percentage of cells in different phases of the cell cycle. 
 
Figure 4.8. Cell cycle profiles across SMCs , BM-MSCs and BM-MSCs differentiated with NF, PDGF-BB 
and TGF-β1 for (A) 7 days (B) 14 days.  Legend: RMSC = BM-MSCs, TGFb = BM-MSCs + TGFβ1, 
PDGF = BM-MSCs + PDGF-BB, No GF = BM-MSCs + NF, ASMC = SMCs. 
 
Cell lines sub G1 G1 S G2 
SMC 9.49 86.15 2.54 1.82 
BM-MSC 0.86 44.09 38.2 16.85 
BM-MSC + NF 1.66 51.59 34.32 12.43 
BM-MSC + PDGF-BB 1.68 44.5 39.35 14.47 
BM-MSC + TGF-β1 2 52.3 32.45 13.25 	  
Table 4.1: Percent gated single cells in different phases of cell cycle observed in SMC, BM-MSCs and 
BM-MSCs differentiated for 7 days in the presence and absence of growth factors.  
 
Cell lines sub G1 G1 S G2 
SMC 14.01 72.78 10.31 2.9 
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Cell lines sub G1 G1 S G2 
BM-MSCs + NF 11.7 48.02 26.54 13.74 
BM-MSCs + PDGF-BB 3.45 45.97 36.95 13.63 
BM-MSCs + TGF-β1 9.71 58.05 22.17 10.07 
 
Table 4.2: Percent gated single cells in different phases of cell cycle observed in SMC, BM-MSCs and 
BM-MSCs differentiated for 14 days in the presence and absence of growth factors.  
 
When the results in Tables 4.1 and 4.2 are compared, they show that a hFN-
coated substrate has no significant effect on mitotic activity of BM-MSCs and those 
differentiated with TGF-β1 exhibit a greater number of cells collectively in the sub G1 
and G1 phase of the cell cycle (suggestive of lower mitotic activity and likely 
differentiated characteristics) compared to PDF-BB or NF treatment. Most SMCs were in 
the sub G1/G1 phase, suggestive of a differentiated state. Longer differentiation time 
results in a lower percentage of cells in the G2, M and S phases. 
4.5 RNA quantification and RT-PCR 
RNA quantification. RNA isolated using the Qiagen kit was quantified using the 
RiboGreen® RNA quantification reagent and kit in order to reverse transcribe known 
amounts of RNA into DNA for the polymerase chain reaction. Since RNA from the 7 day 
and 14 day differentiation cultures were reverse transcribed on different days, two 
standard curves were obtained. The first standard curve corresponds to the absorbances 
obtained for 7 day differentiation RNA samples (Figure 4.9) and the second standard 
curve corresponds to absorbances obtained for 14 day differentiation RNA samples 
(Figure 4.10). Absorbance data from six biological replicates per differentiation 
condition, loaded in duplicates were obtained. The absorbance values were averaged and 
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the average RNA in microgram per microliter were calculated using the slope and 
intercept obtained from the respective standard curves. This value was multiplied by a 
dilution factor of 50 to account for the dilutions when samples were prepared for 
quantification. Since there were variations in the concentration of RNA among the 
samples, a known quantity of RNA (1000 ng) was chosen so that the same amounts of 
RNA were reverse transcribed for PCR.  The concentration of RNA was divided by 1000 
ng to obtain volumes for each biological replicate (Table 4.3).  
 
 
Figure 4.9. Standard curve obtained from the RNA quantification for 7 day differentiation samples.  
 
 
 
Figure 4.10. Standard curve obtained from RNA quantification for 14 day differentiation samples.   
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 7 day 14 day 
Sample RNA (µL) required        
Water (µL)  
(total 15 
µL) 
RNA (µL) 
required        
Water (µL)  
(total 15 
µL) 
MSC_1 1.18 13.82 1.31 13.69 
MSC_2 1.16 13.84 1.44 13.56 
MSC_3 1.17 13.83 2.79 12.21 
MSC_4 1.16 13.84 1.78 13.22 
MSC_5 1.31 13.69 1.56 13.44 
MSC_6 1.44 13.56 1.72 13.28 
SMC_1 4.16 10.84 1.93 13.07 
SMC_2 1.92 13.08 2.74 12.26 
SMC_3 2.38 12.62 2.54 12.46 
SMC_4 2.32 12.68 2.75 12.25 
SMC_5 1.80 13.20 2.40 12.60 
SMC_6 2.64 12.36 2.57 12.43 
NF_1 1.36 13.64 1.30 13.70 
NF_2 1.13 13.87 1.05 13.95 
NF_3 1.72 13.28 1.54 13.46 
NF_4 1.42 13.58 1.74 13.26 
NF_5 1.65 13.35 1.34 13.66 
NF_6 1.05 13.95 1.27 13.73 
P_1 2.18 12.82 1.21 13.79 
P_2 1.34 13.66 1.96 13.04 
P_3 1.40 13.60 1.21 13.79 
P_4 1.34 13.66 1.54 13.46 
P_5 1.10 13.90 15.00 0.00 
P_6 1.27 13.73 1.24 13.76 
T_1 14.60 0.40 2.12 12.88 
T_2 2.20 12.80 2.61 12.39 
T_3 2.01 12.99 5.11 9.89 
T_4 2.29 12.71 9.16 5.84 
T_5 1.73 13.27 1.73 13.27 
T_6 1.68 13.32 1.80 13.20 
Table 4.3. Tables with the volumes of RNA used per treatment condition and time period for PCR. 
Legend: MSC = BM-MSCs, SMCs = SMC, NF = BM-MSCs + NF, P = BM-MSCs + PDGF-BB, T = BM-
MSCs + TGF-β1. 
 
RT-PCR. Treatment-specific expression of three SMC phenotypic protein genes – αSMA, Caldesmon and SMMHC and two genes encoding for elastic matrix/assembly –
elastin and LOX (elastin crosslinking enzyme) were investigated via RT-PCR. The data 
obtained were analyzed using the 2-ΔΔ CT approximation method51. Statistical analysis for 
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PCR data was done using an analysis of variance (ANOVA) to determine overall 
significance in the data. The Tukey HSD and Fisher LSD multiple comparisons were 
used to determined findings that were significant when comparing treatment groups. 
Differences in α-SMA gene expression data for SMC cultured at 7 days versus 14 
days (Figure 4.11) were statistically significant with those cultured for 14 days 
expressing this contractile protein at four times the levels of those cultured for 7 days. 
This finding is not surprising given that SMCs cultured for 14 days had twice the time 
over which time, they likely generated matrix, a microenvironment which enhanced their 
expression of contractile SMC marker proteins.  
 
Figure 4.11. Fold differences in gene expression of αSMA (± standard error) in SMC cultured for 7 and 14 
days. * designates data at different time points per treatment with 95% confidence level. 
 
PCR data with multiple comparisons for αSMA gene expression normalized to 
gene expression data in SMCs is shown in Figure 4.12 and Table 4.4 lists groups that 
differ with p-values < 0.05. Compared to SMCs cultured for 7 days, α-SMA expression 
by BM-MSCs, BM-MSCs treated with PDGF-BB and BM-MSCs treated with TGF-β1 
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were statistically less (p-values < 0.05 listed in Table 4.4). At 7 days of differentiation, 
BM-MSCs treated with and with out growth factors expressed α-SMA at significantly 
higher levels than BM-MSCs alone. When comparing the 7 day differentiation groups, 
BM-MSCs differentiated with TGF-β1 have significantly higher gene expression 
compared with those with PDGF-BB or without cytokines. Whereas, at 14 days of 
differentiation α-SMA gene expression in cultures of BM-MSCs treated with growth 
factors (both PDGF-BB and TGF-β1) was statistically different from BM-MSCs cultured 
with no growth factors. Between the two growth factors used at 14 days of 
differentiation, BM-MSCs differentiated with TGF-β1 have higher gene expression than 
PDGF-BB treated cells. Interestingly, BM-MSCs cultured on hFN substrates with NF 
over 14 days expressed α-SMA mRNA at levels that exceeded that expressed by SMCs, 
indicating that it is a strong determinant of BM-MSC differentiation into SMCs. The fact 
that growth factor treated BM-MSCs at 14 days show less expression of α-SMA mRNA 
relative to the NF case, indicates that growth factor can also modulate in these cases, 
tandem with the hFN substrate, reduce α-SMA mRNA expression.  
The effect of culture period (BM-MSCs and SMCs) and differentiation periods 
(BM-MSCs treated with NF, PDGF-BB and TGF-β1) provided statistically significant 
data designated by ‘*’ for p < 0.05 in Figure 4.12. BM-MSCs cultured for 14 days have 
greater gene expression of αSMA than those cultured for 7 days. This suggests that in 
prolonged culture even on uncoated substrates, BM-MSCs can auto differentiate at least 
partially, to enhance their expression of αSMA. However, BM-MSCs show greater 
expression of this gene when differentiated in the presence of PDGF-BB for 7 days when 
compared to 14 days.  
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Figure 4.12. Fold differences in gene expression of αSMA (± standard error) for BM-MSC differentiated 
with or without growth factors for 7 and 14 days normalized to SMC gene expression. Legend: MSC = 
BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BM-
MSCs + TGF-β1. * designates data at different time points per treatment with 95% confidence level. 
 
Comparison 
Group 
Groups that 
differ 
p-value 
SMC 7d All 7d < 0.05 
 
MSC 7d All 7d < 0.05 
NF 7d TGFb1 0.003 
PDGFbb 7d TGFb1 0.000 
SMC 14d None >0.05 
MSC 14d NF 14d 0.000 
 TGFb1 14d 0.016 
NF 14d  PDGFbb 14d 0.000 
 TGFb1 14d 0.000 
PDGFbb 14d TGFb1 14d 0.036 
Table 4.4. Post-Hoc comparison table with p-values indication significance in fold differences in gene 
expression for αSMA for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs, 
SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB 
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Differences in Caldesmon gene expression data for SMCs cultured at 7 days 
versus 14 days (data not shown) were not statistically significant indicating that longer 
culture time has no effect on the gene expression of Caldesmon in SMCs.  
PCR data with multiple comparisons for Caldesmon gene expression normalized 
to gene expression in SMCs is shown in Figure 4.13. Gene expression levels for 
Caldesmon in BM-MSCs differentiated for 7 days with PDGF-BB or TGF-β1 compared 
to BM-MSCs or BM-MSCs treated without any growth factors showed no statistically 
significant differences (Table 4.5), but appears to be less compared to SMCs. This 
finding suggests that treatment of growth factors for 7 days does not have an effect on 
Caldesmon gene expression, at least at the 7 day differentiation time point. 
At 14 days of culture, BM-MSCs exhibited higher Caldesmon mRNA expression 
levels compared to the 7 day culture group, indicating that the cells may auto-
differentiate, developing more contractile characteristics. However, the gene expression 
levels were still lower than that observed in SMCs at the same time. The caldesmon 
mRNA expression levels in the NF group and TGF-β1 were no different from that in the 
BM-MSC group, indicating lack of effect of hFN substrate and TGF-β1. PDGF-BB 
appeared to enhance gene expression to levels seen in control SMC cultures compared to 
those treated with TGF-β1. Data for 14 day cultures showed no statistically significant 
differences using the Student’s t-test at the 95% confidence level (Table 4.5).  
The effect of differentiation periods (BM-MSCs treated with NF and TGF-β1) 
provided statistically significant data designated by ‘*’ for p < 0.05 in Figure 4.13. BM-
MSCs differentiated with NF and TGF-β1 for 14 days have greater gene expression of 
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Caldesmon than those differentiated for 7 days. This suggests that in prolonged 
differentiation enhance their expression of Caldesmon.  
 
Figure 4.13. Fold differences in gene expression of Caldesmon (± standard error) for BM-MSC 
differentiated with or without growth factors for 7 and 14 days normalized to SMC gene expression. 
Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, 
TGFb1 = BM-MSCs + TGF-β1. * designates data at different time points per treatment with 95% 
confidence level. 
 
Comparison 
Group 
Groups that 
differ 
p-value 
SMC 7d None > 0.05 
MSC 7d None > 0.05 
NF 7d None > 0.05 
SMC 14d NF 14d 0.001 
 TGFb1 14d 0.000 
MSC 14d None > 0.05 
NF 14d  None > 0.05 
 
Table 4.5. Post-Hoc comparison table with p-values indication significance in fold differences in gene 
expression for Caldesmon for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-
MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB 
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Differences in SMMHC gene expression data for SMCs cultured at 7 days versus 
14 days (data not shown) were not statistically significant indicating that longer culture 
time has no effect on the gene expression of SMMHC in SMCs.  
PCR data with multiple comparisons for gene expression for the late-stage SMC 
marker, SMMHC is shown in Figure 4.14. Compared to SMCs cultured for 7 and 14 
days, differences in gene expression by BM-MSCs, BM-MSCs treated with NF and BM-
MSCs treated with PDGF-BB as well as TGF-β1 for SMMHC for the same time period 
were significantly lower (p-values in Table 4.6). Neither the hFN substrate alone, or 
together with either tested growth factor (PGDF-BB or TGF-β1), had any positive effect 
on enhancing SMMHC gene expression in BM-MSCs treated for 7 days (Figure 4.14, 
Table 4.6). 
 
 
 
Figure 4.14. Fold differences in gene expression of SMMHC (± standard error) for BM-MSC 
differentiated with or without growth factors for 7 and 14 days normalized to SMC gene expression. 
Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, 
TGFb1 = BM-MSCs + TGF-β1. * designates data at different time points per treatment with 95% 
confidence level. 
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Comparison 
group 
Groups that 
differ 
p-value 
SMC 7d All 7d < 0.05 
MSC 7d All 7d < 0.05 
SMC 14d All 14d <0.05 
MSC 14d SMCs 14d 0.005 
 TGFb1 7d 0.045 
NF 14d PDGFbb 14d 0.026 
 TGFb1 14d 0.016 
 
Table 4.6. Post-Hoc comparison table with p-values indication significance in fold differences in gene 
expression for SMMHC for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs, 
SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB 
 
Gene expression levels for SMMHC in 14 day cultures compared to 7 day 
cultures appear to be higher in the case of BM-MSCs and BM-MSCs treated without any 
growth factors suggesting a long culture period may enhance gene expression. Also, the 
NF group at 14 days have significantly higher SMMHC expression levels compared to 
either growth factor treated cultures. But, BM-MSCs treated with PDGF-BB and TGF-β1 
at 14 day cultures appear to have lower gene expression levels for SMMHC compared to 
7 day counterparts suggesting that growth factor treatment may reduce SMMHC gene 
expression. However in, neither case, the differences are statistically significant (p-values 
> 0.05). The TGF-β1 treated group for  7 days have significantly higher gene expression 
than those differentiated for 14 days indicating that longer differentiation period with this 
growth factor may decrease SMMHC expression. 
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Differences in elastin gene expression data for SMCs cultured at 7 days versus 14 
days (data not shown) were not statistically significant indicating that longer culture time 
has no effect on the gene expression of elastin in SMCs.  
Figure 4.15 shows treatment and cell type-specific differences in Elastin mRNA 
expression. There was essentially no difference between undifferentiated BM-MSCs 
cultured for 7 and 14 days on uncoated plastic; the expression levels remained much 
lower than the terminally differentiated adult SMCs, whose expression also remained 
unchanged between 7 and 14 days of culture. This confirms that undifferentiated BM-
MSCs are far less elastogenic than are SMCs. At the 7 days of attempted differentiation, 
NF  and PDGF-BB cultures had significantly lower Elastin gene expression than those 
differentiated with TGF-β1, indicating that TGF-β1 positively enhances elastin gene 
expression (Table 4.7). 
 
 Figure 4.15. Fold differences in gene expression of Elastin (± standard error) for BM-MSC differentiated 
with or without growth factors for 7 and 14 days normalized to SMC gene expression. Legend: MSC = 
BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BM-
MSCs + TGF-β1. * designates data at different time points per treatment with 95% confidence level. 
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Comparison 
Group 
Groups that 
differ 
p-value 
SMC 7d All < 0.05 
MSC 7d NF 7d 0.005 
 TGFB1 7d 0.000 
NF 7d TGFb1 7d 0.001 
PDGFbb 7d TGFb1 7d 0.000 
SMC 14d MSC 14d 0.000 
 NF 14d 0.000 
 TGFb1 14d 0.000 
NF 14d  None > 0.05 
 
Table 4.7. Post-Hoc comparison table with p-values indication significance in fold differences in gene 
expression for Elastin for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs, 
SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB 
 
At the 14 days of attempted differentiation of the BM-MSCs in the presence of a 
hFN-coated substrate alone (no factors), or together with PDGF-BB or TGF-β1, 
expressed the elastin gene at statistically lower levels when compared to SMCs (Table 
4.7) and in general, expression levels appeared consistently higher than the 
undifferentiated BM-MSCs. Although BM-MSCs differentiated with growth factors 
(PDGF-BB and TGF-β1) as well as no factors appear to be significantly higher in elastin 
gene expression, data were not statistically significant indicating that longer 
differentiation period may not enhance elastin gene expression, except in the case of NF 
(7 versus 14 days). 
Differences in lysyl oxidase (LOX) gene expression data for SMCs cultured at 7 
days versus 14 days (data not shown) were not statistically significant indicating that 
longer culture time has no effect on the gene expression of LOX in SMCs.  
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Figure 4.16 shows treatment and cell type-specific differences in LOX mRNA 
expression. There were statistical differences between undifferentiated BM-MSCs 
cultured for 7 and 14 days on uncoated plastic but the expression levels remained much 
lower than the terminally differentiated adult SMCs, whose expression also remained 
unchanged between 7 and 14 days of culture. This confirms that undifferentiated BM-
MSCs produce far less amounts of LOX than SMCs. At the 7 days of attempted 
differentiation of the BM-MSCs in the presence of a hFN-coated substrate alone (no 
factors), or together with PDGF-BB or TGF-β1, did not result in any statistically 
significant increases (Table 4.8) in LOX gene expression. 
 
Figure 4.16. Fold differences in gene expression of LOX (± standard error) for BM-MSC differentiated 
with or without growth factors for 7 and 14 days normalized to SMC gene expression. Legend: MSC = 
BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BM-
MSCs + TGF-β1. * designates data at different time points per treatment with 95% confidence level. 
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* 
* 
* 
0.0 
0.1 
1.0 
10.0 
MSC SMC NF PDGFbb TGFb1 
Fo
ld
 in
cr
ea
se
 in
 g
en
e 
ex
pr
es
si
on
 
7day differentiation/culture 14day differentiation/culture 
  89 
Comparison 
Group 
Groups that 
differ 
p-value 
 TGFb1 7d 0.037 
MSC 7d NF 7d 0.000 
 TGFb1 7d 0.002 
NF 7d None > 0.05 
SMCs 14d None > 0.05 
MSC 14d None > 0.05 
NF 14d  PGFbb 14d 0.048 
 TGFb1 14d 0.004 
 
Table 4.8. Post-Hoc comparison table with p-values indication significance in fold differences in gene 
expression for LOX for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs, 
SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB 
 
Gene expression for LOX in BM-MSC and BM-MSCs differentiated with and 
without growth factors remained significantly lower than SMCs cultured for 14 days 
(Table 4.8). At the 14 days of attempted differentiation of the BM-MSCs in the presence 
of a hFN-coated substrate along with basal media (no factors) showed significantly 
higher LOX gene expression when compared with PDGF-BB or TGF-β1 (Table 4.8). 
Longer culture period for undifferentiated BM-MSCs notably enhances LOX gene 
expression whereas for NF and TGF-β1 treated cultures, expression is reduced.  
4.6 DNA assay for cell proliferation 
DNA assay was performed at day 1 and day 28 of culture for each treatment 
condition, and the positive (SMCs) and negative (undifferentiated BM-MSCs) cell types. 
In general, as seen in Figures 4.17 and 4.18, proliferation of undifferentiated BM-
MSCs (subjected to 7 and 14 days of pre-culture) over 28 days was significantly higher 
than that of likewise-cultured SMCs (significance values listed in Table 4.9 and Table 
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4.10). The BM-MSCs that had been cultured for 14 days, thereafter proliferated more 
slowly than did BM-MSCs that had been pre-cultured for 7 days, suggesting some degree 
of auto-differentiation or at least phenotypic change with longer culture time.  
Compared to the corresponding undifferentiated BM-MSC controls, BM-MSCs 
cultured without any factors on hFN substrates, showed lower cell numbers after 28 days 
of culture, with 14 day pre-cultured cells proliferating less than the 7-day pre-cultured 
cells. This suggests that culture on hFN substrates drives some degree of 
differentiation/phenotypic change in BM-MSCs and that longer periods of pre-culture 
enhance such change. The apparent outcomes of culture on hFN substrates in absence of 
differentiation-promoting growth factors agree well with that deduced from phenotypic 
analysis of cells in Sections 4.2 and 4.5. When sought to be cultured with PDGF-BB over 
7 days following expansion for 28 days, no significant differences were noted in cell 
number (Figure 4.17) compared to the NF cultures although significantly higher cell 
numbers were observed compared to TGF-β1 treated cultures confirming the mitogenic 
nature of PDGF-BB. During the 14 day differentiation of BM-MSCs with TGF-β1, cell 
numbers were significantly lower than those treated with PDGF-BB or NF indicating that 
this growth factor may contribute to a more differentiated phenotype compared to other 
treatments. 
Cells expanded after 14 days of differentiation with NF, PDGF-BB and TGF-β1 
showed far fewer cell counts at 28 days of culture, relative to the corresponding 7 day 
differentiated cells, suggesting that these cells were significantly more differentiated, 
though not quite terminally differentiated as with our SMC cultures. These results align 
very closely that of flow cytometry and immunofluorescence analysis in indicating that 
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PDGF-BB induces delayed differentiation of BM-MSCs into SMCs unlike TGF-β1, 
which achieves this at an earlier time (7 days versus 14 days). 
When fold increases in cell number were plotted (Figure 4.18), the fold increases 
in cell number for PDGF-BB treated cells was much greater than for the NF cultures, 
suggesting lack of differentiation during 7 and 14 day differentiation with PDGF-BB. In 
the case of TGF-β1, the proliferation of cells after the differentiation period was slower 
than in the corresponding NF cultures, suggesting some degree of phenotypic 
change/differentiation had occurred in the short time frame (7 days).  
 
 
Figure 4.17. DNA results showing the effect of differentiation time (7 versus 14 day) on cell numbers at 
the end of day 28 cultures. Data plotted are average cell numbers ± standard error. Legend: MSC = BM-
MSCs, SMC = SMCs, NF = BM-MSCs+ NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BM-MSCs + 
TGF-β1, * designates significance of difference between 7 and 14 day differentiation period deemed for p < 
0.05. 
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PDGFbb 7d TGFb1 7d 0.000 
SMC 14d All 14d 0.000 
MSC 14d PDGFbb 14d 0.024 
 TGFb1 14d 0.009 
NF 14d TGFb1 14d 0.010 
 
Table 4.9. Post-Hoc comparison table with p-values indication significance in cell proliferation for cells 
cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs 
+ NF, PDGFbb = BM-MSCs + PDGF-BB 
 
 
Figure 4.18. Fold increases reported for 28-day culture period in cell number for BM-MSCs differentiated 
for 7 or 14 days in presence or absence of growth factors. Data plotted represent the mean fold increases ± 
standard error. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs+ NF, PDGFbb = BM-MSCs + 
PDGF-BB, TGFb1 = BM-MSCs + TGF-β1. 
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MSC 7d All 7d < 0.05 
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SMC 14d All 14d < 0.05 
MSC 14d PDGFbb 14d 0.012 
 TGFb1 14d 0.017 
NF 14d PDGFbb 14d 0.010 
 TGFb1 14d 0.002 
PGFbb 14d TGFb1 14 d 0.022 
 
Table 4.10. Post-Hoc comparison table with p-values indication significance in cell proliferation fold 
changes for cells cultured or differentiated for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, 
NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB 
 
4.7 Fastin assay for elastin quantification 
Results obtained from the Fastin assay for both the alkali insoluble and soluble 
fractions were normalized to amounts of DNA (indicative of # of cells) obtained from the 
fluorometric DNA assay (Section 4.6).  
As presented in Figure 4.19, undifferentiated BM-MSCs subjected to 7 and 14 
days of pre-culture produce dramatically lower amounts of insoluble elastin compared to 
SMCs cultured for the same time period (significance listed in Table 4.11). There seems 
to be no difference in the amounts of insoluble elastin produced by BM-MSCs cultured 
for 7 days versus 14 days suggesting that longer culture time does not play a role in 
enhancing the amounts of insoluble elastin produced by the undifferentiated cells. 
Compared to the corresponding undifferentiated BM-MSC controls, BM-MSCs cultured 
without any factors on hFN substrates for 7 and 14 days, showed no significant increases 
in the amounts of insoluble elastin in the ECM suggesting that a hFN substrate alone 
which we showed earlier to coax some degree of differentiation of the BM-MSCs, is 
insufficient in coaxing these cells to produce significant amounts of cross-linked matrix 
elastin. The treatment of BM-MSCs with PDGF-BB on an hFN substrate for 7 days 
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seems to significantly reduce the amounts of insoluble elastin present in the ECM by half 
whereas the 14 day treatment appears to significantly enhance these levels. The data 
suggests that BM-MSCs treated with PDGF-BB for 14 days may be necessary to enhane 
elastin protein production. BM-MSCs treated with TGF-β1 for 7 days produced lower 
amounts of cross-linked matrix elastin than did BM-MSCs but produced better amounts 
compared with those treated with PDGF-BB or undifferentiated BM-MSCs for the same 
duration. Like PDGF-BB, BM-MSCs treated with TGF-β1 for 14 days produced greater 
amounts of insoluble elastin than those differentiated for 7 days. This suggests that 
although BM-MSCs do not produce the amounts of insoluble cross-linked matrix elastin 
as do SMCs cultured for the same period, those differentiated for a longer time point, 
seem to produce better results overall. 
 
Figure 4.19. Insoluble elastin in the extracellular matrix normalized to amounts of DNA obtained from 
fluorometric DNA assay. Legend: MSC – BM-MSCs, SMC – SMCs, NF – BM-MSCs = NF, PDGFbb – 
BM-MSCs + PDGF-BB, TGFb1 – BM-MSCs + TGF-β1.  
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Comparison 
group 
Groups that 
differ 
p-value 
SMC 7d All 7d < 0.05 
MSC 7d PDGFbb 7d 0.007 
NF 7d PDGFbb 7d 0.001 
PDGFbb 7d TGFb1 7d 0.003 
SMC 14d All 14d < 0.05 
NF 14d PDGFbb 14 d 0.003 
 
Table 4.11. Post-Hoc comparison table with p-values of insoluble elastin for cells cultured or differentiated 
for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-
MSCs + PDGF-BB 
 
Figure 4.20 shows that BM-MSCs subjected to 7 and 14 days of pre-culture 
produce dramatically lower amounts of soluble elastin compared to SMCs cultured for 
the same time period (significance listed in Table 4.12). BM-MSCs cultured for 14 days 
seem to produce twice the amounts of alkali-soluble matrix elastin compared to those 
cultured for 7 days suggesting that longer culture time may be required to significantly 
enhance elastin pre-cursor production. Compared to the corresponding undifferentiated 
BM-MSC controls, BM-MSCs cultured without any factors on hFN substrates, showed 
lower amounts of soluble elastin in the ECM suggesting that a hFN substrate alone is 
insufficient in coaxing BM-MSCs toward tropoelastin production. The treatment of BM-
MSCs with PDGF-BB on an hFN substrate for 7 days seems to reduce the amounts of 
soluble elastin present in the ECM whereas the same treatment for 14 days appears to 
enhance tropoelastin levels. The data suggests that BM-MSCs treated with PDGF-BB for 
14 days and not 7 days may be necessary to enhance elastin protein production. BM-
MSCs treated with TGF-β1 for 7 days produced the same amounts of tropoelastin 
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compared to BM-MSCs differentiated in the absence of growth factors but higher 
amounts of protein are seen in the 14 day differentiation group. Comparing 7 days versus 
14 days of differentiation, it appears from Figure 4.20 that BM-MSCs treated with 
growth factors (PDGF-BB and TGF-β1) for 14 days produced more alkali-soluble matrix 
elastin than their 7 day differentiated counterparts with TGF-β1 treated cells for 14 days 
producing the highest amounts of alkali soluble elastin. 
 
 
Figure 4.20. Alkali-soluble elastin in the extracellular matrix normalized to amounts of DNA obtained 
from fluorometric DNA assay. Legend: MSC – BM-MSCs, SMC – SMCs, NF – BM-MSCs = NF, 
PDGFbb – BM-MSCs + PDGF-BB, TGFb1 – BM-MSCs + TGF-β1. 
 
Comparison 
group 
Groups that 
differ 
p-value 
SMC 7d All 7d < 0.05 
MSC 7d PDGFbb 7d 0.013 
NF 7d PDGFbb 7d 0.041 
PDGFbb 7d TGFb1 7d 0.012 
* 
* 
* * 
0 
10 
20 
30 
40 
50 
60 
70 
80 
MSC SMC NF PDGFbb TGFb1 
A
lk
al
i-s
ol
ub
le
 M
at
ri
x 
E
la
st
in
 / 
D
N
A
   
 [n
g/
ng
] 
7 day differentiation/culture 14 day differentiation/culture 
  97 
Comparison 
group 
Groups that 
differ 
p-value 
SMC 14d All 14d < 0.05 
NF 14d PDGFbb 14d 0.007 
 TGFb1 14d 0.022 
 
Table 4.12. Post-Hoc comparison table with p-values of soluble elastin for cells cultured or differentiated 
for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-
MSCs + PDGF-BB 
 
4.8 Hydroxyproline assay for collagen quantification 
The hydroxyproline assay results were normalized to cell number obtained from 
the fluorometric DNA assay (Section 4.6) to account for variations in initial seeding 
density and proliferation rate.  
Figure 4.21 shows that BM-MSCs subjected to 7 and 14 days of pre-culture 
produce dramatically lower amounts of collagen compared to SMCs cultured for the 
same time period (significance listed in Table 4.13). There is no difference in collagen 
amounts by BM-MSCs cultured for 7 or 14 days suggesting that longer culture time has 
no effect on collagen production in BM-MSCs. Compared to the corresponding 
undifferentiated BM-MSC controls, BM-MSCs cultured without any factors on hFN 
substrates and TGF-β1 for 7 days, showed significantly higher amounts of ECM 
collagen. The treatment of BM-MSCs with PDGF-BB on an hFN substrate for 7 days 
seems to increase the amounts of collagen produced whereas the same treatment for 14 
days appears to decrease its levels. The data suggests that BM-MSCs treated with PDGF-
BB for 7 days and not 14 days produce greater amounts of collagen, although data is not 
statistically significant. Longer differentiation time in the case of NF and TGF-β1 treated 
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cultures seem to significantly produce lower amounts of ECM collagen. Data obtained 
from this experiment suggests that differentiation via growth factors alone under the 
conditions tested is not enough to coax the differentiated cells to produce the amounts of 
elastin necessary for a vascular matrix an elastogenic agent may be necessary to enhance 
the outcomes of interest. 
 
 
Figure 4.21. Amounts of collagen normalized to cell count obtained from fluorometric DNA assay in 
SMC, BM-MSCs and BM-MSCs differentiated in the presence and absence of growth factors. Legend: 
MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = 
BM-MSCs + TGF-β1.  
 
Comparison 
group 
Groups that 
differ 
p-value 
SMCs 7d None > 0.05 
MSC 7d NF 7d 0.023 
 TGFb1 7d 0.007 
SMCs 14d All 14d < 0.05 
 
Table 4.13. Post-Hoc comparison table with p-values of collagen for cells cultured or differentiated for 7 
and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-MSCs + 
PDGF-BB 
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4.9 LOX activity assay 
The LOX activity assay results were normalized to cell number obtained from the 
fluorometric DNA assay (Section 4.6) to account for variations in initial seeding density 
and proliferation rate.  
  
 
Figure 4.22. Average amounts of peroxide produced by SMC, BM-MSCs and BM-MSCs differentiated in 
the presence and absence of growth factors. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + 
NF, PDGFbb = BM-MSCs + PDGF-BB, TGFb1 = BM-MSCs + TGF-β1. 
 
Comparison 
group 
Groups that 
differ 
p-value 
SMC 7d MSC 7d 0.008 
MSC 7d All 7d < 0.05 
SMC 14d MSC 14d 0.019 
MSC 14d All 14d < 0.05 
Table 4.14. Post-Hoc comparison table with p-values of LOX amounts for cells cultured or differentiated 
for 7 and 14 days. Legend: MSC = BM-MSCs, SMC = SMCs, NF = BM-MSCs + NF, PDGFbb = BM-
MSCs + PDGF-BB 
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Although Figure 4.22 shows that both 7 and 14 day undifferentiated BM-MSC 
cultures produce the greatest amounts peroxide indicating that these cultures also produce 
more LOX than any other treatment group. However, gene expression studies of LOX 
(Figure 4.16) and the Fastin elastin assay (Figures 4.19 and 4.20) revealed this group to 
have lower gene expression as well as elastin protein production. Therefore, the results of 
this assay are inconsistent with previous findings and may need to be further analyzed for 
accuracy.  
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CHAPTER V 
CONCLUSIONS AND RECOMMENDATIONS 
 
5.1 Conclusions 
1. Immunohistochemistry data for SMC specific markers showed positive alpha 
smooth muscle actin (α-SMA) staining in PDGF-BB and TGF-β1 (7 and 14 day) 
treated BM-MSCs compared to those cultured without growth factors. All the 
cultures expressed Calponin (expect NF at 7 days) and SM22-α (except NF and 
TGF-β1 at 7 days). Quantitative analysis revealed that PDGF-BB increases the 
expression of α-SMA per cell in treated BM-MSCs for 7 days when compared to 
the other conditions, whereas, TGF-β1 increases the expression of Calponin in 14 
day differentiation cultures.  
2. Flow cytometry results indicated that BM-MSCs differentiated with TGF-β1, 
especially for 14 days more intensely express SMC markers, especially a-SMA 
compared to other markers.  
3. Cycle cycle analysis indicated that hFN-coated substrate does not affect 
differentiation capacity or BM-MSCs and treated with TGF-β1 exhibit a greater 
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number of cells in the G1 phase of the cell cycle compared to PDF-BB-treated 
BM-MSCs.  
4. Real time polymerase chain reaction (RT-PCR) data show higher expression of α-
SMA in BM-MSCs differentiated for 7 and 14 days with and without cytokines 
compared to BM-MSCs. The greatest expression was found in BM-MSCs 
differentiated in the absence of cytokines (14 days) and in TGF-β1 cultures 
differentiated for 7 days. Elastin gene expression was greatest in the 14 day TGF- 
β1 treated cultures and there was no difference in gene expression between 
treatment or control groups for Caldesmon.  
5. Cell proliferation data showed that 7 day differentiation groups had lower cellular 
proliferation and BM-MSCs treated with PDGF-BB and TGF-β1 for 14 days had 
lower expression compared to others. Comparing the effect of differentiation 
time, those cultured for 14 days showed lower cellular proliferation in all groups 
except SMCs. Like wise, fold change data exhibited that TGF-β1 treated BM-
MSCs for both 7 and 14 days were far less proliferative than any other group. 
6. Fastin elastin assay showed that BM-MSCs treated with PDGF-BB produced 
greater amounts of insoluble and soluble elastin compared to all other groups. 
7. Hydroxyproline assay showed no significant differences between BM-MSCs 
treated and untreated with cytokines for 7 and 14 day and control cell lines except 
SMCs. 
8. LOX activity assay showed inconsistent results when compared to RT-PCR data 
and fastin elastin assay.  
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However, overall evidence from various experiments suggests growth-factor 
mediated differentiation into SMC-like cells is possible although terminal differentiation 
was not observed under currently tested conditions. The immunofluorescence results of 
this study - positive staining for α-SMA, Calponin and SM-22α are consistent with the 
findings published by Gong and Niklason48 and Ross J.J. et al33. However, positive 
staining for SMMHC was not observed. Results from RT-PCR for α-SMA gene 
expression in TGF-β1 treated cultures for 7 days coincide with findings by Ross J.J. et 
al33 but, SMMHC gene expression in this study produced opposite results. Investigation 
of elastin in ECM produced by BM-MSC derived SMC has been studied by very few 
groups if at all any.  
5.2 Limitations and recommendations 
This study was limited by several factors and the proposed solutions may enhance 
the current results obtained.  
1. Passage number – The commercially purchased BM-MSCs were of passage 4 
(due to availability) and upon propagation became passage 5 for use in 
differentiation experiments. Since the protocol provided by the company 
recommended using passage 5 or lower for differentiation experiments, the use of 
passage 5 in this study may have affected the differentiation outcomes and 
perhaps using a lower passage number cell line may have produced better results. 
2. Mixed cell population – It may have been possible to have obtained a population 
of cells with mixed lineages at the end of the differentiation experiments which 
would have drastically affected the outcome observed in this study. To overcome 
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this limitation, employing cell sorting and the end of the differentiation phase may 
have resulted in a greater population of SMC-like cells.  
3. Differentiation time - Since the cell culture period for BM-MSCs were limited to 
7 and 14 days, the time may not have been long enough to observe the effect of 
cytokines on the differentiation potential. Longer differentiation time may have 
produced cells that are closer to the SMC phenotypes. The reversal of 
differentiation capability of BM-MSCs after removal of differentiation medium 
may have been a possibility and needs to be further assessed.  
4. Elastin and Elastic matrix enhancement - During the propagation phase of this 
study post differentiation, cells were not treated with exogenous elastin producing 
factors such as Hyluronan to facilitate elastic matrix production as demonstrated 
previously in our lab52.  
5. Growth substrate and compliance – The substrate used for this study was hFN 
which, although present in the ECM in vivo to enhance cell adhesion, does not 
provide the scaffolding experienced by stem cells in vivo such as collagen and 
fibrillin. Using a scaffold with circumferentially aligned fibers may enhance the 
production of ECM components, specifically tropoelastin and LOX and aid in the 
cross-linking of elastin precursors into the insoluble elastic matrix seen in blood 
vessels. Since we tested differentiation on stiff tissue culture plastic, a systematic 
examination needs to be conducted to investigate the role of substrate compliance. 
Compliant substrates have shown to increase differentiation outcomes.  
6. 3-D culture environment – This study was done in a two dimensional (2-D) 
microenvironment that does not mimic the native blood vessel environment. 
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Perhaps differentiating BM-MSCs in a bioreactor perfused so that to mimic 
hemodynamic forces experienced in the body may produce better results in 
differentiation and ECM production.  
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